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INTRACELLULAR SIGNALING MECHANISMS OF  
RESISTANCE TO EGFR-TARGETING AGENTS 
 
The epidermal growth factor receptor (EGFR) is widely expressed in head and neck 
squamous cell carcinomas (HNSCC) and activates many growth and survival pathways within 
tumor cells.  EGFR-targeting agents are only modestly effective in treating HNSCC, however, 
and a consistent mechanism of resistance has not been identified, in part, due to the paucity of 
preclinical models.  This dissertation focuses on generating EGFR-inhibitor resistant preclinical 
models in order to identify biomarkers that may be predictive of response to these agents.   
We have assessed the response of a panel of HNSCC cell lines to the EGFR inhibitors 
erlotinib and cetuximab to determine their relevance as models of resistance to these agents.  We 
defined a narrow range of response to erlotinib in HNSCC cells in vitro.  We attempted to 
generate models of cetuximab resistance in cell line-derived xenografts and heterotopic 
tumorgrafts directly from primary HNSCC patient tumors.   Our studies in HNSCC suggest that 
heterotopic xenografts are more representative of patient response to cetuximab than cell-line 
derived xenografts, although we did establish a model of cetuximab resistance from bladder 
cancer cell line-derived xenografts.   
A candidate-based approach was used to examine the role of HER2, HER3, and c-Met on 
mediating EGFR inhibitor resistance.  We identified increased phosphorylation of a carboxyl-
terminal fragment of HER2 (611-CTF) in cetuximab-resistant cells.  Afatinib, an irreversible 
kinase inhibitor targeting EGFR and HER2, successfully restored cetuximab sensitivity in vitro.  
When afatinib was combined with cetuximab in vivo, we observed an additive growth inhibitory 
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effect in cetuximab-resistant xenografts.  We also show that while c-Met activity is not sufficient 
to alter cellular response to erlotinib, concomitant inhibition of c-Met and EGFR is required for 
the deactivation of MAPK in the presence of stimulatory ligands. These data support the 
proposed role for co-targeting c-Met with EGFR in the treatment of HNSCC. 
The studies presented here are significant because, in addition to suggesting that 611-
CTF may be a novel biomarker for cetuximab resistance, they provide a thorough assessment of 
modeling EGFR inhibitor resistance in HNSCC and suggest heterotopic tumorgrafts as a 
plausible new model for examining cetuximab resistance in future studies. 
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1.0  INTRODUCTION 
1.1 THE EPIDERMAL GROWTH FACTOR RECEPTOR 
1.1.1 EGFR is a Growth Factor Receptor and Tyrosine Kinase 
Epidermal growth factor (EGF) was originally identified as a factor causing tooth 
eruption and eyelid opening in neonatal mice[1, 2].  The epidermal growth factor receptor 
(EGFR) was later identified as the membranous receptor for this growth factor[3].  EGFR is a 
1210 amino acid protein containing four extracellular domains, a transmembrane domain, and an 
intracellular kinase domain followed by a carboxyl-terminal tail containing several tyrosine 
residues[4] (Figure 1-1). 
EGFR is a tyrosine kinase that is extensively phosphorylated on its carboxyl-terminal tail 
often following stimulation with ligands such as EGF[5].  EGFR currently has seven known 
ligands, including EGF, Transforming Growth Factor Alpha (TGFα), amphiregulin, betacellulin, 
epiregulin, epigen, and heparin-binding EGF[1, 6-11] (Figure 1-1).  Each of these ligands 
contains an EGF-like domain that interacts with extracellular domains I and III of EGFR[12].  
Ligand binding to EGFR causes stabilization of EGFR in an open conformation, permitting 
receptor dimerization via inter-molecular interactions in domain II of the extracellular region[13] 
(Figure 1-1). 
 21 
  
 
Figure 1-1. The ErbB Family of Tyrosine Kinase Receptors. 
A. Each ErbB family member has specific ligands that stabilize the receptors in their open conformation with the 
exception of HER2, which is ligand-independent. B. The monomeric, tethered structure of EGFR, HER3, and HER4 
is shown, as well as the dimeric (untethered) structure of these receptors.  Because HER2 is ligand-independent, it 
resembles the untethered structure even when monomeric.  The four subunits of the cytoplasmic domain are 
represented as I-IV.  Domains I & III are leucine-rich domains and II & IV are cysteine-rich domains.  Interactions 
between two domain IIs during dimerization bring the intracellular kinase domains into close proximity and enable 
transphosphorylation of tyrosine residues.  The tyrosine kinase domains contain a C-lobe (C), an N-lobe (N), and an 
activation loop (A), all of which are required for full kinase activity.  C. While all four ErbB family members are 
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theoretically capable of homodimerization, only specific endogenous heterodimer pairs have been discovered.  This 
figure is original artwork by Kelly Quesnelle as published in Molecular Pathology: Head and Neck Cancer in 
Gelmann E, Sawyers C, Rauscher F (Eds), Molecular Oncology: Causes of Cancer and Targets for Treatment. New 
York, NY: Cambridge University Press. 
 
EGFR phosphorylation is achieved through receptor dimerization or aggregation[14] 
which can be mediated by receptor overexpression[15, 16] or, more commonly, ligand-
dependent mechanisms.  Phosphorylation of EGFR activates the receptor because it enhances 
EGFR kinase activity by increasing the binding affinity of its substrates and the rate of substrate 
phosphorylation[17].  Ligand-independent activation of EGFR can also occur by mutations that 
render it constitutively active[18], overexpression of urokinase plasminogen activator receptor 
via integrin α5B[19], or the silencing of phosphatases which shifts basal levels of EGFR 
phosphorylation to the activated state[20].  Crosstalk with G-protein-coupled receptors (GPCRs) 
is another potential mechanism of ligand-independent EGFR activation[21]. 
1.1.2 Member of the ErbB Family of Tyrosine Kinase Receptors 
EGFR is a member of the ErbB family of human epidermal growth factor receptor (HER) 
tyrosine kinases consisting of EGFR (ErbB1), HER2 (ErbB2, Neu), HER3 (ErbB3), and HER4 
(ErbB4).  Each receptor has a cysteine-rich extracellular region, a transmembrane domain, and 
an intracellular kinase domain that is highly conserved within the family, although HER3 lacks 
inherent kinase activity[22].  Likewise, HER2 has long been considered ligand-independent[23, 
24], stabilized naturally in the in the open, dimer-permissive conformation.  Both homodimers 
and heterodimers are known to occur within the ErbB Family of receptors (Figure 1-1), and the 
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ligand-independent nature of HER2 combined with HER3’s lack of intrinsic kinase activity 
bolster the need for familial heterodimerization to impart downstream signaling[12, 24].  
Importantly, new studies have described in detail the asymmetric nature of ErbB dimerization, 
opening the door for future shifts in the paradigm that ErbB family members apart from HER2 
function in a ligand:receptor ratio of 2:2[25, 26]. 
The ErbB Family members are most often found on epithelial cells and stromal cells, 
naturally occurring basolaterally on epithelial cells to facilitate communication with the 
mesoderm which contains a wealth of growth factors[27].  Growth factors, including the ligands 
for EGFR and the other ErbB family members, are often expressed in the mesoderm as 
membrane-bound precursors that are cleaved by metalloproteinases and other extracellular 
proteases[28, 29].  These soluble growth factors generated from mesenchymal cells can then act 
in a paracrine manner to signal growth cascades in normal epithelial cells containing ErbB 
family members. 
Once activated, ErbB receptors recruit adapter molecules such as clathrin that promote 
receptor endocytosis.  Receptors are still active signaling molecules in the endocytic vesicle[30], 
from which receptors are either recycled[31] or sorted to the lysosome for degradation[32] based 
on ligand occupancy and prolonged kinase activity.  In EGFR, binding of Casitas b-lineage 
lymphoma (CBL), either directly or through GRB2 at phosphotyrosine residues within the 
intracellular domain of EGFR results in ubiquitin-mediated trafficking to either the lysosome for 
recycling or the late endosome for degradation, respectively[33].  Interestingly, receptor 
endocytosis and downregulation are more prevalent with EGFR than the other members of the 
ErbB family[34], suggesting the importance of EGFR within the family as a the key temporal 
regulator of signaling.  There is also increasing evidence that ErbB family members may 
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translocate to the nucleus and serve as transcription factors[35], although the endogenous role of 
this process in cellular growth remains elusive. 
1.1.3 Role of EGFR in Cancer 
EGFR has been implicated in human cancer for over twenty years[4, 36].  The main 
mechanisms of increased EGFR activation in oncogenesis are receptor overexpression and a shift 
from paracrine to autocrine signaling.  Autocrine signaling occurs when a cell produces both a 
ligand and its receptor, as is the case in cancerous cells that often express both EGFR and its 
ligand, TGFα, leading to uncontrolled cell growth[37].   Expression levels of TGFα and EGFR 
are increased in tumor cells as well as in the adjacent “normal” mucosa[38, 39], indicating that 
the upregulation of these genes is an early event in carcinogenesis.  Further, expression levels of 
both TGFα and EGFR within tumors are associated with adverse patient outcome[40], which 
suggests that not only is the switch to autocrine signaling an early event in carcinogenesis but 
also a persistent phenomenon in tumor progression.   
EGFR and/or the other ErbB family members are overexpressed or otherwise implicated 
in many solid tumor carcinomas including esophageal, gastric, colorectal, pancreatic, 
hepatocellular, breast, endometrial, ovarian, prostate, lung, head and neck, and glioma[41-54].  
Co-expression of EGFR with multiple members of the ErbB family is indicative of worse 
outcome than EGFR alone[55].  HER2 and HER3 have known oncogenic functions in several 
cancer types, but the role of HER4 in cancer is more controversial.  Unlike other family 
members, HER4 is not correlated with advanced malignant phenotypes such as angiogenesis, 
tumor progression, or metastasis[56]. 
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1.1.3.1 EGFR in Squamous Cell Carcinoma of the Head and Neck 
Head and neck cancer accounts for approximately 4% of all malignancies in the United 
States[57] and it is the sixth most common cancer worldwide, indicating the large public health 
problem presented by head and neck cancers[58]. The five year survival rate for squamous cell 
carcinoma of the head and neck is approximately 50% and is highly dependent on the stage at 
diagnosis[59]. In addition to smoking and drinking, human papillomavirus (HPV) has been 
implicated in a significant subset of oropharyngeal cancers, particularly in cancers that arise in 
patients under the age of forty-five[60].  p53 is also mutated in a large percentage of head and 
neck cancers[61], generally independently of HPV infection[62].  Because HPV is known to 
degrade p53 protein[63], these data suggest the importance of p53 as the main molecular 
alteration in HNSCC. 
EGFR is also known to play a role in the molecular pathogenesis of HNSCC.  Wild-type 
EGFR protein, as detected by immunohistochemistry (IHC), is found to be expressed at 
moderate to high levels in up to ninety percent of HNSCC tumors by IHC[64].  Transcriptional 
activation contributes to increased EGFR expression levels and may represent the primary 
mechanism of EGFR overexpression in HNSCC[65].  Elevation of EGFR at the protein level has 
been detected in up to ninety percent of head and neck cancer patients, and expression levels 
correlate with poor patient survival[66]. HER2 is expressed at moderate to low levels in 
HNSCC[67], and HER3 expression is increased in HNSCC as compared to normal oral 
epithelium[68].  HER4 is not expressed in HNSCC[69]. 
There are several mechanisms of regulation that may alter EGFR transcript or protein 
levels in HNSCC, including rates of transcription, synthesis, and degradation. Gene transcription 
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of EGFR is abrogated by environmental factors that inhibit autocrine signaling of the receptor 
through TGFα[65].  Amplifications of EGFR at the genetic level have also been reported in a 
fraction of HNSCC[70, 71] and seem to occur mainly in HPV-negative tumors[72].  Patients 
with increased gene copy numbers and/or expression levels of EGFR have a significantly higher 
instance of progression and poorer survival[71, 73, 74].  Furthermore, expression of TGFα in 
primary HNSCC tumors is associated with decreased survival indicating a role for autocrine 
EGFR activation in HNSCC tumorigenesis[40, 75, 76]. 
A well-characterized mutation of EGFR, EGFRvIII, accounts for a large amount of 
ligand-independent EGFR activation in HNSCC[77]. The EGFRvIII variant is a frameshift 
deletion in the extracellular domain of the receptor that results in constitutive activation of the 
receptor[78] (Figure 1-2). Since EGFRvIII is constitutively active and lacks a ligand binding 
domain, it may be resistant to antibodies or drugs that inhibit cellular growth in other places 
apart from the kinase domain of EGFR[77, 79, 80].  It is worth noting that EGFRvIII expression 
is lost in vitro in head and neck cancer cell lines so endogenous data on this variant is sparse[81].  
These cumulative findings indicate an important role for EGFR in HNSCC tumorigenesis and 
progression. 
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Figure 1-2. The EGFRvIII Mutation. 
The EGFRvIII mutation is characterized by a frameshift mutation resulting in deletion of exons 2-7 as shown.  
Domains are represented as labeled rectangles with numbered exon boundaries. Abbreviations: TM=transmembrane 
domain; N=N-lobe; A=Activation loop; C=C-lobe; P=Autophosphorylation domain. This figure is original artwork 
by Kelly Quesnelle as published in Molecular Pathology: Head and Neck Cancer in Gelmann E, Sawyers C, 
Rauscher F (Eds), Molecular Oncology: Causes of Cancer and Targets for Treatment. New York, NY: Cambridge 
University Press. 
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1.1.4 EGFR Signaling & Cellular Function 
EGFR signaling is involved in diverse cellular processes including growth, 
differentiation, and survival[82]. The main downstream signaling cascades for EGFR include: 
Src Family Kinases (SFK), Mitogen Activated Protein Kinases (MAPK), Signal Transducers and 
Activators of Transcription (STAT), and Protein Kinase B, also known as AKT (Figure 1-3). 
Activated EGFR can bind and phosphorylate Src and other Src Family Kinases, which 
serve as oncogenic protein tyrosine kinases within the cell when activated by EGFR or other 
mechanisms[83].  Ligand binding to EGFR has been shown to activate STAT1, STAT3, and 
STAT5 via Src[84].  Additionally, EGFR has been shown to be phosphorylated by c-Src on 
Y845[85] and STAT5b may be activated downstream of this pathway, providing a means by 
which c-Src indirectly activates STAT5b through EGFR[86].  Src is also known to activate Ras 
for subsequent activation of the MAPK pathway[87, 88]. 
STAT proteins serve as transcription factors whose target genes identified to date 
contribute to a broad scope of functions including proliferation, differentiation, and survival[89].  
Of all the STAT proteins, STAT3 target genes have been most thoroughly investigated.  STAT3 
target genes involved in cell cycle regulation include those encoding CyclinD1, CyclinD3, c-
Myc, p21wafl, and p27.  Vascular Endothelial Growth Factor (VEGF) is the product of a STAT3 
target gene involved in angiogenesis, and MMP-2 and MMP-9 are products of STAT3 target 
genes that contribute to migration and invasion.  STAT3 target genes involved in the inhibition 
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of apoptosis include Survivin, Mcl-1, and Bcl-XL[90].  EGFR is known to activate STAT 
proteins directly[91] or indirectly through Src (as described above) or Janus Kinases (JAK). 
The role for JAKs in ligand-induced EGFR activation of STAT3 is cell-type dependent.  
JAKs provide maximal activation of STAT proteins in an EGF-dependent signaling scenario.  
Inhibiting JAKs in breast cancer cell lines, however, only partially blocks EGF-dependent STAT 
protein activation, further supporting the role of Src in STAT-mediated EGFR signaling.  In the 
absence of EGF stimulation, Src and JAK cooperate to mediate STAT3 signaling in breast 
cancer cell lines.  However, in the presence of EGF stimulation, STAT3 is activated via EGFR 
and Src kinase activity is cooperative but not required[92]. 
Proline-rich Tyrosine Kinase 2 (PYK2) has been implicated as a co-mediator of STAT 
protein activation with c-Src in response to EGF stimulation.  Treatment of breast cancer cells 
with EGF induced STAT3-mediated cell proliferation by recruiting c-Src, PYK2 and STAT3 to 
EGFR where STAT3 is phosphorylated at Y705[93].  Forced expression of EGFR did not, 
however, increase phosphorylation of STAT3 at Y705, suggesting that EGFR is required for 
phosphorylation at this specific residue, but is not a sufficient catalyst for this event.  This could 
also be due to negative regulation in the MAPK pathway, where MAPK1 activation caused by 
EGFR activation inhibited STAT3 phosphorylation at Y705[94]. 
Ligand-activated EGFR commonly signals downstream to the Ras/Raf/MAPK pathway 
mediating cell proliferation and survival.  In this pathway, Growth Factor Receptor-Bound 
Protein 2 (GRB2) activates Son of Sevenless (SOS), which dissociates GDP from Ras to permit 
GTP binding as Ras activation[95].  Ras subsequently activates Raf and PI3K, in turn, indirectly 
activates many proteins required for cellular growth including Nuclear Factor Kappa-light-chain-
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enhancer of Activated B Cells (NF-kB), cAMP Response Element-binding (CREB), Ets-1, 
activator protein 1 (AP-1) and c-Myc[96].  Because there is a great deal of overlap between 
MAPK- and STAT-mediated signaling pathways, there is also tremendous amount of feedback 
between these two pathways. 
In breast cancer cell lines, GRB2 and STAT3 bind to the same tyrosine phosphorylation 
sites on EGFR (Y1086 and Y1068), which enables further negative regulation to occur when 
GRB2 binds to EGFR with a higher affinity than STAT3.  GRB2 has a similar regulatory effect 
on STAT1, but not STAT5a[97].  This is not the only scenario in which competitive binding to 
EGFR is shown to negatively regulate STAT protein activation.  Physical interaction of STAT1 
and STAT3 with EGFR occurs across multiple domains in the carboxyl terminus of EGFR.  
SOCS-1 and SOCS-3 also interact with the cytoplasmic domain of EGFR, likely inducing 
ubiquitination and degradation of ligand-bound EGFR and resulting in a decrease of STAT1 and 
STAT3 activation[98].  
TGFα stimulates proliferation of esophageal carcinoma cell lines via autocrine signaling 
through EGFR, and is shown to stimulate constitutive activation of STAT3[99].  Increased 
STAT3 activation increases proliferation in head and neck cancer cells and is caused, at least in 
part, by TGFα-mediated activation of EGFR[100].  Treatment of HNSCC cell lines with TGFα 
has also been shown to increase activation of several Src family kinases[101].  
Another large downstream signaling pathway for EGFR is the AKT pathway.  AKT is 
localized to the membrane when it binds phosphatidylinositol 3,4,5-triphosphate (PIP3). This 
membrane localization results in the subsequent phosphorylation, or activation, of AKT by 
phosphoinositide dependent kinase 1 (PDK1) or mammalian target of rapamycin complex 2 
 31 
(mTORC2)[102]. PIP3 is the phosphorylated form of phosphatidylinositol 4,5-bisphosphate 
(PIP2).  This phosphorylation is carried out by phosphoinositide-3-kinase (PI3K), which can be 
activated directly or indirectly by EGFR[103].  Once activated, AKT is involved in cell growth, 
invasion, metastasis, and resistance to apoptosis[104]. 
 
Figure 1-3. EGFR Signaling 
The EGFR signaling pathway is very diverse and can be alternatively activated by several other molecules including 
integrins, GPCRs, c-Met, VEGF, and Src.  IL-6 bound to GP130 can activate the STAT pathway. GPCRs can 
activate MAPK directly or activate EGFR via Src phosphorylation.  Both Hepatocyte Growth Factor (HGF) and 
VEGF can activate the MAPK pathway independently of EGFR, the latter in an autocrine fashion.  This figure is 
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original artwork by Kelly Quesnelle as published in Molecular Pathology: Head and Neck Cancer in Gelmann E, 
Sawyers C, Rauscher F (Eds), Molecular Oncology: Causes of Cancer and Targets for Treatment. New York, NY: 
Cambridge University Press. 
 
 
1.2 PHARMACOLOGIC INHIBITON OF EGFR 
There are currently two primary approaches to targeting EGFR, monoclonal antibodies 
against EGFR (mAb) and small molecule tyrosine kinase inhibitors (TKI) specific for EGFR.  
Alternative approaches to targeting EGFR include an antisense oligonucleotide of EGFR[105] 
and biologics and compounds that target multiple family members of the ErbB family[106].  The 
work in this dissertation focuses primarily on mAbs and TKIs that target EGFR since these are 
the most widely used EGFR-targeting agents. 
1.2.1 Tyrosine Kinase Inhibitors 
Small molecule TKIs bind directly into the adenosine triphosphate (ATP)-binding pocket 
of the tyrosine kinase domain thus preventing phosphate transfer and signaling[107].  There are 
currently two TKIs with exquisite sensitivity to EGFR that have been approved for use in the 
United States by the Food and Drug Administration (FDA).  The first, gefitinib, was approved 
for use in non-small cell lung cancer (NSCLC)[108] but is currently under review for market 
withdrawal due to lack of clinical response and because of the approval of erlotinib, another TKI 
that targets EGFR[109].  Erlotinib currently has FDA-approval for use in pancreatic cancer and 
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NSCLC and is in late clinical development for use in head and neck cancer.  It is unknown 
whether erlotinib and gefitinib are equally effective in the treatment of cancer, but they have 
similar response rates in clinical trials[110, 111].  The main advantage to erlotinib over gefitinib 
is FDA approval of a stronger dosing regimen for erlotinib as compared to gefitinib[112].    
Despite widespread expression of EGFR in many cancer types, reported response rates to 
erlotinib in cancers that do not harbor EGFR mutations are modest (around 4%) when erlotinib is 
used as monotherapy [113] or in conjunction with other chemotherapies (around 21%)[114, 115]. 
EGFR mutations exist in lung cancer that enhance tumor sensitivity to gefitinib and 
erlotinib to roughly 75%[108, 116, 117].  The L858R mutation increases the affinity of EGFR 
for ATP, increasing its kinase activity by 50% compared to wild type[118].  A loss of four amino 
acids in exon 19, the LREA deletion, also permits enhanced kinase activity although the precise 
mechanisms of this activity has not been reported[119]. These two mutations account for over 
90% of the EGFR inhibitor sensitizing mutations in lung cancer[112].  These mutations are not 
found in other cancers such as HNSCC[120]. 
1.2.2 Monoclonal Antibodies 
There are currently two monoclonal antibodies approved for use in the United States by 
the FDA.  Cetuximab, a chimeric human-mouse mAb, directly blocks the function of EGFR by 
binding to the ectodomain and preventing ligand binding and subsequent receptor activation[121, 
122]. Cetuximab is also capable of activating an anti-tumor immune response termed antibody-
dependent cell mediated cytotoxicity (ADCC)[123, 124].  Cetuximab increases responsiveness of 
head and neck cancer patients to radiation therapy from 64% with radiation alone to 74% with 
radiation plus cetuximab[125].  Likewise, cetuximab increases responsiveness of head and neck 
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tumors to other chemotherapies.  A response rate of 20% is observed with other chemotherapies 
alone and this increased to 36% when cetuximab added to the treatment regimen[126].  When 
used as a monotherapy, however, the response rate to cetuximab alone is a modest 10-13%[127].  
Cetuximab is currently FDA approved for use in head and neck cancer and colorectal 
cancer[125, 128].   
Panitumumab is a fully humanized EGFR monoclonal antibody against EGFR that differs 
in its isotype (IgG2) from cetuximab (IgG1), which leads to different mechanisms of immune-
mediated cell death.  Namely, panitumumab does not activate ADCC in the same way that 
cetuximab does due their differing isotypes[129].  Panitumumab is currently approved for use in 
colorectal cancer and has response rates around 10%[130]. 
Mutations that are known to confer sensitivity to EGFR-targeting TKIs do not seem to 
play a role in altering sensitivity to EGFR mAbs in clinical trials[131, 132].  Preclinical data is 
more variable, however.  Animal studies show enhanced sensitivity to cetuximab in the context 
of the L858R mutation[133, 134], but no benefit is seen when cetuximab is administered in the 
setting of exon 19 deletion[134].   
Taken together, monotherapy data from mAbs and TKIs targeting EGFR suggest that 
EGFR targeting alone may not be as effective as predicted by the widespread expression and 
activation of EGFR. Further, there does not appear to be a consistent biomarker or mutation that 
can predict response to these agents in many solid tumor types[125, 135] as mutations in the 
tyrosine kinase domain of EGFR that confer sensitivity to EGFR-targeting agents in lung cancer 
are not present in all cancer types[136]. 
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1.3 RESISTANCE TO EGFR INHIBITORS 
1.3.1 Primary Resistance to EGFR Inhibitors 
Primary resistance, or de novo resistance, occurs when a tumor never responds to certain 
chemotherapy.  Primary resistance is known to occur with both erlotinib and cetuximab, and also 
in the context of EGFR-activating mutations despite their increased response rate to EGFR TKIs.  
While nearly 75% of EGFR mutant tumors respond to EGFR TKIs, 25% of mutant NSCLCs 
demonstrate primary resistance[137].  Most tumors, apart from a subset of NSCLC, lack EGFR 
sensitizing mutations and are not responsive to EGFR TKIs at all[138]. 
There are very few trials where cetuximab has been used as a monotherapy based on the 
general lack of response to its use in this manner.  Monotherapy response rates to cetuximab are 
stagnant around 10% in both head and neck and colorectal cancer, indicating that some 90% of 
patients do not respond to cetuximab when used as a monotherapy[127, 139].  Combination 
treatments are the most successful when cetuximab is combined with radiation, but even in these 
cases 25% of patients do not respond to cetuximab[125]. 
1.3.2 Acquired Resistance to EGFR Inhibitors 
Acquired resistance to EGFR TKIs is a phenomenon that occurs in virtually all patients 
treated with EGFR TKIs, despite the presence of EGFR sensitizing mutations in NSCLC[140].  
The following definition of acquired resistance to an EGFR inhibitor was presented by  Jackman, 
Pao, Engleman, Kris, Janne, Lynch, Johnson, and Miller for use in NSCLC[141]: 
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“We propose the following criteria be used to define more precisely acquired resistance 
to EGFR TKIs. All patients should have the following criteria: previous treatment with a single-
agent EGFR TKI (e.g., gefitinib or erlotinib); either or both of the following: a tumor that 
harbors an EGFR mutation known to be associated with drug sensitivity or objective clinical 
benefit from treatment with an EGFR TKI; systemic progression of disease…while on continuous 
treatment with gefitinib or erlotinib within the last 30 days; and no intervening systemic therapy 
between cessation of gefitinib or erlotinib and initiation of new therapy.” 
Acquired resistance to cetuximab is a common occurrence, although not one that is 
(literally) defined as well as acquired resistance to EGFR TKIs.  The phenomenon of disease 
progression during treatment with cetuximab is documented, however.  One recent study 
described disease progression in 298/599 patients (49.7%) receiving cetuximab plus 
chemotherapy for front-line treatment of metastatic colorectal cancer[142].  The study authors 
observed, on average, an increase in time to progression of 1.2 months when cetuximab is added 
to the standard, front-line treatment regimen for metastatic colorectal cancers that lack mutations 
known to alter response to EGFR targeting agents.  Again, these data along with other studies 
demonstrate the widespread phenomenon of acquired resistance to cetuximab. 
1.3.3 Somatic Mutations & Gene Amplifications Associated with Resistance to EGFR 
Inhibitors 
The most common genetic alteration resulting in resistance to EGFR inhibitors is the 
T790M mutation in lung cancer.  This “gatekeeper” mutation replaces the drug-permissive 
threonine in the catalytic cleft of EGFR with a bulkier methionine residue to prevent binding of 
EGFR TKIs to EGFR.  The T790M mutation occurs as a secondary mutation in approximately 
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50% of NSCLC tumors that harbor EGFR activating mutations[140, 143].  Rarely, the T790M 
mutation occurs in patients with lung cancer who have not been treated previously with an EGFR 
TKI[144].  Recent studies show that 2/369 (0.54%) patients with NSCLC who have not had prior 
treatment with EGFR TKI appear to harbor T790M mutations[145], and there is evidence to 
suggest that this mutation confers enhanced kinase activity in addition to TKI resistance[146].  
Importantly, there is no evidence that this mutation occurs in any cancer type other than 
NSCLC[120]. 
Mutations are also known to occur in the GTPase domain of K-Ras, both in NSCLC and 
in colon cancer.  These activating K-Ras mutations obviate the need for EGFR signaling to drive 
cell growth in tumors and, as such, confer resistance to both EGFR TKI and mAbs.  In NSCLC, 
K-Ras mutation occurs in 15-25% of tumors with wild type EGFR and are associated with 
primary resistance to EGFR TKIs[147].  In lung cancer, K-Ras mutations occur at a rate of 43% 
and are associated with primary resistance to mAbs[148, 149].  K-Ras mutations are rare in 
HNSCC and other cancers and have not been associated with resistance to EGFR inhibitors in 
these cancer types[150].  
Finally, genomic amplification of c-Met has been identified as a mechanism of resistance 
to EGFR TKI in both EGFR wild type and EGFR-L8585R lung cancer.  In NSCLC tumors, c-
Met is amplified at a rate of 22% in EGFR-TKI resistant tumors harboring the EGFR-L858R 
mutation[151].   c-Met amplification can also occur at rates up to 5% in NSCLC tumors with 
wild type EGFR and wild type K-Ras[152].   
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1.3.4 Signaling Mechanisms of Resistance to EGFR Inhibitors 
Pinpointing mechanisms of resistance to EGFR-targeted therapy has proven difficult. 
EGFR signaling is promiscuous (Figure 1-3) and no consistent genetic alteration appears to 
confer resistance or sensitivity to EGFR targeting agents.  EGFR mediates some of the most 
potent and redundant signaling pathways in cancer cells, including the MAPK, AKT, and 
JAK/STAT pathways. These pathways can be activated by cytokines or other growth 
factors[153] (Figure 1-3). Additionally, GPCRs can provide a means of resistance to EGFR-
targeted antibodies by activating the autophosphorylation domains of EGFR directly[21].   
Combination therapies that target two or more molecules involved in oncogenesis may 
prove to be the most efficacious modality when trying to limit off-target side effects.  In vitro 
studies have suggested that alternative signaling may drive resistance to EGFR tyrosine kinase 
inhibitors in some cancers due to the redundancy of growth factor receptors on intracellular 
signaling cascades[154-156].  c-Met, the hepatocyte growth factor receptor, contributes to TKI 
resistance in lung cancer by activating MAPK in an EGFR-independent fashion[157] and is over 
expressed in many cancer types including HNSCC[158].  Increased activation of c-Met mediated 
by HGF has been shown to cause primary resistance to EGFR TKIs in EGFR mutant lung 
cancer[159, 160].  The role of Src and c-Met and the therapeutic potential of targeting these 
pathways concurrently with EGFR is currently being investigated in head and neck cancers.  Src 
is a downstream effector molecule of EGFR in both the AKT and MAPK pathways that can be 
activated by other kinases, such as c-Met, independent of EGFR.  Dimerization with HER2 or 
HER3 has also been identified as a mechanism of resistance to inhibitors targeting EGFR[154].  
EGFR targeting in conjunction with inhibitors of VEGF and/or GPCRs are also ongoing.  As the 
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molecular scaffolding underlying EGFR signaling becomes better understood, these combination 
therapies will continue to evolve.   
1.4 RATIONALE, HYPOTHESIS, AND SPECIFIC AIMS 
1.4.1 Rationale & Hypothesis 
Despite ubiquitous expression of EGFR in HNSCC, FDA-approved agents targeting 
EGFR are only effective in a subset of patients, suggesting that alternative signaling mechanisms 
may be activated in the setting of EGFR blockade. There are currently no known HNSCC 
mutations that can serve as the basis for prospectively identifying patients who are likely to 
benefit from EGFR targeting.  While results of one trial suggested that lower expression levels of 
EGFR correlated with response to cetuximab when administered in combination with cisplatin 
chemotherapy, other studies have failed to corroborate this association[125, 135]. HPV-positive 
HNSCCs have a better prognosis, regardless of therapy, but no association between HPV and 
response to EGFR-targeting agents has been reported.  
Elucidation of mechanisms of resistance to EGFR inhibitors has been limited by: 1) the 
difficulty in obtaining post-treatment tissue from patients treated with EGFR inhibitors; and 2) 
the paucity of preclinical models of EGFR inhibitor resistance. Two preclinical models of 
resistance to EGFR-targeting agents are reported. One model is frequently generated in the 
literature and consists of cell clones selected for gefitinib resistance[161, 162] and the other is 
cell clones selected for cetuximab resistance from Dr. Paul Harari at the University of 
Wisconsin[162, 163].  Both of these models were generated by prolonged exposure to EGFR 
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inhibition in vitro and the cetuximab resistant model has not been consistent in vivo[162, 164]. 
Therefore, to determine mechanisms of EGFR inhibitor resistance, additional preclinical models 
are needed.  
HNSCC represents an ideal model in which to study such mechanisms since two major 
classes of EGFR-targeting agents are either FDA-approved (cetuximab, monoclonal antibody) or 
under clinical investigation (erlotinib, tyrosine kinase inhibitor, TKI).  I hypothesize that 
signaling through alternative pathways including c-Met, HER2, and/or HER3, is associated 
with resistance to EGFR-targeting agents. I propose to generate preclinical models of 
resistance to EGFR inhibitors to identify biomarkers or pathways associated with EGFR inhibitor 
resistance that can be targeted to enhance response to EGFR blockade. I plan to accomplish these 
goals by addressing the following specific aims: 
 
1.4.2 Specific Aim 1: To Examine the Role of c-Met, HER2 and HER3 in EGFR-
Targeting Antibody Resistance 
Published literature suggests increased phosphorylation of HER2 and HER3 in 
cetuximab-resistant models[163]. I will generate in vivo models of acquired resistance to 
cetuximab.  Cetuximab-resistant cells will be stably transfected with HER2 and/or HER3 shRNA 
to determine the contribution of HER2 and/or HER3 signaling to the cetuximab resistance 
phenotype. Interrogation of signaling molecules downstream of HER2 and/or HER3, along with 
combination targeting of EGFR, HER2, and/or HER3 both in vitro and in vivo, will elucidate 
downstream signaling pathways that can be inhibited to overcome cetuximab resistance. Forced 
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expression of HER2 and/or HER3 will determine if either or both of these ErbB receptors are 
sufficient for cetuximab-resistance in HNSCC. Differences in c-Met protein expression and/or 
phosphorylation will also be assessed in these models. 
 
1.4.3 Specific Aim2: To Examine the Role of c-Met, HER2, and HER3 in EGFR Kinase 
Inhibitor Resistance 
My preliminary results indicate increased phosphorylation of c-Met in TKI-resistant cells 
and a subsequent enhanced sensitivity to c-Met kinase inhibitors in these cells. The role of c-Met 
in mediating response to EGFR TKI will be determined using c-Met siRNA in vitro and by 
targeting c-Met in TKI-resistant xenografts in vivo. Forced expression of c-Met will be examined 
to determine if c-Met is sufficient for TKI resistance in HNSCC. Differences in HER2 and HER3 
protein expression and/or phosphorylation will also be assessed in these models. 
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2.0  PRECLINICAL MODELING OF EGFR INHIBITOR RESISTANCE 
2.1 INTRODUCTION 
Valid preclinical models of EGFR inhibitor resistance are a prerequisite for 
understanding the molecular mechanisms that may contribute to such resistance.  In these studies 
we sought to probe a panel of HNSCC cell lines for their response to the EGFR targeting agents 
erlotinib and cetuximab with the goal of generating preclinical models of resistance to these 
agents.   
2.1.1 Modeling Erlotinib Resistance 
Several groups have generated models of acquired resistance to erlotinib using HNSCC 
cells[158, 162].  These models have been created by exposing an erlotinib-sensitive cancer cell 
line to increasing concentrations of erlotinib in vitro over an extended period of time.  This 
serves as a means by which to study acquired resistance to erlotinib, which is thought to occur 
eventually in nearly all patients who are treated with erlotinib (Paragraph 1.3.2). 
Studies suggest that the majority of EGFR expressing tumors, however, demonstrate 
primary resistance to EGFR TKIs (Paragraph 1.3.1).  Modeling primary resistance to erlotinib in 
preclinical models has been challenging due to the relatively arbitrary nature of establishing dose 
thresholds for erlotinib response using in vitro cell systems.  Many breast and lung cancer cell 
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lines demonstrate IC50s values that are below 10µM for erlotinib whereas acquired models of 
erlotinib resistance typically have IC50s values exceeding 10µM[165, 166].  The intratumoral 
concentration of erlotinib has not been reported, however, so defining any threshold of resistance 
in vitro is subjective and may not be representative of patient response. 
2.1.2 Modeling Cetuximab Resistance 
Approximately 25% of patients have primary resistance to cetuximab when used with 
radiation (Paragraph 1.3.1) and there are published preclinical models of this type in gastric 
cancer[167] and lung cancer[168] but currently no preclinical models of primary resistance in 
HNSCC have been published to date.  This may be due to challenges of detecting growth 
inhibition with cetuximab treatment in vitro.  Cetuximab produces strong anti-tumor effects on 
human cancer cells in vivo[169, 170], but it has sub-optimal anti-proliferative effects in 
vitro[171, 172] and is best modeled in vitro using invasion assays[173].   
Alternatively, estimates suggest that acquired resistance to cetuximab occurs in roughly 
50% of wild-type K-Ras patients with colon cancer receiving cetuximab (Paragraph 1.3.2).   
Such resistance is traditionally modeled by growing cells in vitro under chronic exposure to 
increasing concentrations of drug to select for cells that can grow in the presence of cetuximab.  
This approach has been used to generate models of resistance to cetuximab in lung cancer[163] 
and HNSCC, although the reproducibility of these models has been challenging[164].   
Efforts to generate models of cetuximab resistance from wild type tissues in vivo have 
been unsuccessful to date.  One group was able to generate xenografts derived from a colon 
cancer cell line that re-grew in the presence of cetuximab, but these tumors were generated from 
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a cell line known to harbor an activating K-Ras mutation[174, 175].  Another group generated an 
in vivo model of cetuximab resistance but was unable to culture cells from their cetuximab 
resistant xenografts[171].  A consistent preclinical model of cetuximab resistance would enable 
us to better elucidate the mechanisms driving this resistance and could serve as a tool with which 
to probe combination therapies that may enhance the efficacy of cetuximab. 
2.2 MATERIALS AND METHODS 
2.2.1 Cells and Reagents 
SCC1 was derived from a primary HNSCC tumor and both SCC1 and the cetuximab-
resistant clone SCC1c8 were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with 
10% fetal bovine serum (FBS) and 0.4ug/mL hydrocortisone [163].  HN-5, OSC-19, PCI-52, 
UM-22A, CAL33, 1483, and CAL27 are primary HNSCC cell lines and UM-22B, 686LN, and 
PCI-15B are derived from metastatic cervical lymph nodes from patients with HNSCC[176].  
OSC-19 cells were maintained in Modified Eagle Medium (MEM) with 10% FBS and 1% non-
essential amino acids.  HN-5 and 686LN cells were maintained in DMEM/F-12 + 10% FBS.  
PCI-52, PCI-15B, UM-22A, UM-22B, CAL33, 1483, CAL27, T24, and A431 cells were 
maintained in DMEM + 10% FBS.  T24 is derived from a transitional bladder carcinoma[177] 
and A431 is an epidermoid carcinoma of the vulva[178].  UM-22A and UM-22B cells were a 
generous gift from Dr. Tom Carey (University of Michigan) and PCI-52 and PCI-15B cells were 
a generous gift from Dr. Theresa Whiteside (University of Pittsburgh).  HeLa cells are a cervical 
cancer cell line maintained in DMEM + 10% FBS[179].  All cell lines were validated by 
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genotyping within 6 months of their use using the AmpFISTR Identifiler System (Applied 
Biosystems).  Cetuximab-resistant clones were maintained in media with 100nM cetuximab.  
Cetuximab (Erbitux, ImClone Systems and Bristol-Myers Squibb) was purchased from the 
University of Pittsburgh Pharmacy. Afatinib was obtained from Boehringer Ingelheim as a 
powder and resuspended in DMSO for in vitro studies or 0.5% methylcellulose with 0.4% tween 
80 in saline for animal studies. Trastuzumab (Herceptin, Genentech) was purchased from the 
University of Pittsburgh Pharmacy and diluted as recommended in the package insert.  Erlotinib 
was purchased from Chemietek and resuspended in DMSO for cell studies and methyl cellulose 
for animal studies. 
2.2.2 Cell Line Xenograft Modeling 
Subcutaneous xenografts were generated from six different epithelial cancer cell lines 
(T24, CAL33, A431, OSC-19, SCC1, and SCC1c8) (n=6 for all cell lines except T24 where 
n=12) in athymic nude mice using one million cells with Matrigel (BD Biosciences).  After 
tumor formation (7-10 days), mice received 0.8mg of cetuximab by intraperitoneal (i.p.) 
injection twice weekly. Tumors were measured twice weekly. If tumors progressed after 14 days 
of treatment, dosing was increased to 1.0mg of cetuximab twice weekly and then 0.8mg of 
cetuximab three times per week after 28 days. If no tumors were present, the animal was 
sacrificed after 90 days of treatment. If tumors were present, the animal was sacrificed at 90 days 
or when the tumor diameter exceeded 20mm.  Tumors were removed, digested, and suspended as 
single cells, which were propagated in culture and re-inoculated as two subcutaneous xenografts. 
These tumors were treated with 0.8mg of cetuximab three times per week immediately following 
tumor formation.   
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For the HNSCC cetuximab model generation, subcutaneous xenografts were created from 
PCI-52, UM-22A, UM-22B, CAL27, HN-5, 1483, OSC-19, SCC1, SCC1c8, and CAL33 cell 
lines.  Two million cells were inoculated subcutaneously onto each flank of athymic nude mice 
(n=6 xenografts per cell line). Cetuximab treatment was initiated at 0.2mg twice weekly by i.p. 
injection immediately following tumor formation (generally 7-14 days post-inoculation) for PCI-
52, UM-22A, CAL27, HN-5, 1483, OSC-19, SCC1, and SCC1c8 cells.  Cetuximab treatment 
was initiated by i.p. injection at 0.02mg twice weekly in UM-22B cells once median tumor 
volume exceeded 50mm3 (generally 7-14 days post-inoculation).  After the first week at these 
doses, cetuximab dose was increased to 0.04mg five times per week.  After two weeks at this 
dose, cetuximab dose was increased to 0.2mg twice weekly for the remainder of the study. 
Cetuximab treatment was initiated at 0.02mg twice weekly by i.p. injection in CAL33 cells once 
the median tumor volume exceeded 300mm3 (generally 7-14 days post-inoculation).  Cetuximab 
dosing was increased to 0.04mg twice weekly after one the first week of treatment and 0.08mg 
twice weekly after the second week of treatment.  Following two weeks of treatment at 0.08mg 
twice weekly, cetuximab dose was increased to 0.2mg twice weekly for the remainder of the 
study.  A summary of the dosing scheme is provided (Table 2-1). 
2.2.3 HNSCC Tumorgraft Modeling 
For HNSCC tumorgraft model generation, tumors were generated as follows.  Following 
HNSCC tumor resection, patient samples were quality controlled by the University of Pittsburgh 
Medical Center’s Department of Pathology for 70% tumor composition, de-identified, and 
delivered in antibiotic/antimycotic solution.  Tissues were collected under the auspices of a tissue 
bank protocol approved by the University of Pittsburgh Institutional Review Board. Tumor 
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samples were cut into 25mg pieces and fresh frozen or used for implantation.  Non-obese 
diabetic/severe combined immunodeficiency (NOD/SCID) mice that are interleukin 2R gamma 
null (Jackson Laboratories; Bar Harbor, ME) were anesthetized using isofluorane and a small 
incision made in the flank.  25mg of patient tumor was placed in the pocket of the incision site 
and the wound closed with surgical adhesive.  Analgesic was administered and the animals were 
monitored until fully ambulatory.  Mice were kept in isolation for 7-10 days and checked daily 
for wound healing.  Mice were checked weekly for tumor formation. 
Once tumor size reached approximately 50mm3, generally 4-6 weeks after surgery, mice 
were treated with 0.02mg of cetuximab by i.p. injection twice weekly.  These tumors can be 
referred to as passage 1.  When tumor size increased beyond the maximum allowable size under 
IACUC guidelines, the animals were sacrificed and 25mg of the tumor was used to create new 
tumorgrafts in 2-4 animals as described above, this time termed passage 2.  This process was 
repeated and the data shown here are from passage 3.  Passage 2 tumors received cetuximab at 
0.04mg of cetuximab twice weekly.  Passage 3 tumors received cetuximab initially at 0.08mg 
twice weekly, then this dose was increased to 0.2mg twice weekly. 
2.2.4 Single Agent Treatment Animal Studies  
 For the differential sensitivity study using T24 and T24PR3 cells treated with cetuximab, 
one million parental and resistant cells were blindly injected on opposite flanks of the same 
mouse (n=7 mice) with Matrigel.  Treatment began following tumor formation.  Animals were 
treated with 2.0mg of cetuximab three times weekly by i.p. injection.   
 48 
For the differential sensitivity study using CAL33 and CAL33B cells treated with 
cetuximab, two million CAL33 or CAL33B cells were blindly injected on opposite flanks of the 
same mouse (n=5 mice).  Treatment began once median tumor volume exceeded 50mm3  
(generally 7-14 days post-inoculation).  Animals were treated with 0.2mg of cetuximab twice 
weekly by i.p. injection. 
For the comparative studies using erlotinib and cetuximab to treat xenografts derived 
from 686LN and HeLa cells, one million cells were injected subcutaneously with Matrigel (BD 
Biosciences).  686LN and HeLa cells were inoculated on opposite flanks of athymic nude mice 
(n=9 mice per treatment).  Following tumor formation (7-10 days post-inoculation), animals 
were treated with erlotinib or cetuximab.  Erlotinib was administered at 50mg/kg five times per 
week by oral gavage.  Cetuximab was administered as 1.0mg twice weekly by i.p. injection.    
2.2.5 Metabolic Activity Assays 
Cells were plated to 50% confluency a 24-well plate.  Media was changed to contain new 
media and the appropriate drug or control at 24 hours.  3-(4,5-Dimethylthiazol-2-Yl)-2,5-
Diphenyltetrazolium Bromide (MTT) was added for 30 minutes 72 hours following drug 
treatment.  Cells were rinsed with phosphate buffered saline (PBS) and lysed with dimethyl 
sulfoxide (DMSO).  DMSO extracts were measured at 570nm in an uQuant spectrophotometer to 
determine formazan production versus standard controls.  Each drug treatment or control was run 
in triplicate wells and the data shown here is the result of three independent experiments.   
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2.2.6 Flow Cytometry 
Flow cytometry was conducted at the UPCI Flow Cytometry Core Facility using a 
Beckman Coulter MoFlo High Speed Sorter.  α-EGFR (ab-Cam) was labeled with Alexa 
Fluor488 (Invitrogen) and cells were counter-stained with Propidium Iodine.  Propidium-Iodine 
labeled cells were excluded from analysis, then cells were bracketed to capture a low percentage 
tail population of EGFR-null cells on 686LN.  These same brackets were applied to the HeLa 
cell line and gated events were calculated from 50,000 live events for each cell line. 
2.2.7 Immunoblotting 
Immunoblots were performed on cell lysates collected at 70-80% confluency in normal 
growth media.  Lysates were resolved on sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) gels and transferred to nitrocellulose membranes prior to antibody 
staining (EGFR, BD Transduction Lab; pAKT and AKT, Cell Signaling).  Densitometry was 
performed using Image J. 
2.2.8 Invasion Assays 
Five thousand cells were plated in the inner well of a Matrigel Invasion Chamber (BD 
Biosciences) in serum free-media. Wells were placed into media containing 10% FBS and drugs 
were added to both chambers where indicated.  After 24 hours, cells invading through the 
Matrigel coated membrane were stained and counted.   
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2.2.9 Statistical Analyses 
Erlotinib relative IC50 with associated 95% confidence intervals were calculated using 
GraphPad Prism v5.0. All nonlinear regression curves for erlotinib response had an R2 value 
greater than 0.70.  P-values were generated for invasion assays using a homoscedastic two-tailed 
Student’s t-Test.  Nonparametric Spearman correlations were used to determine the relationship 
of EGFR protein levels to erlotinib IC50.  Statistical analysis for single agent treatment animal 
studies was conducted using non-paired, two-tailed student’s t-tests. 
2.3 RESULTS 
2.3.1 Generation of a Cetuximab-Resistant Preclinical Model 
In order to study mechanisms of cetuximab resistance, we created a preclinical model 
based on the previously published in vivo generated model of trastuzumab-resistance[180].  
Subcutaneous tumor xenografts were established using five cetuximab-sensitive epithelial cancer 
cell lines (T24, CAL33, A431, OSC-19, SCC1) as well as one previously described cetuximab-
resistant epithelial cancer cell line, SCC1c8[163].  These cell lines were chosen because we 
originally thought they were a panel of HNSCC cell lines (UM-22B, 1483, CAL33, OSC-19, and 
SCC1, SCC1c8) with the vulva carcinoma cell line, A431.  A431 was the original cell line used 
for the discovery of cetuximab and a cetuximab sensitive control in this experiment[181].  Upon 
retrospective cellular genotyping, however, we determined that the UM-22B and 1483 cell lines 
were actually the T24 transitional bladder cancer cell line.  Nevertheless, T24, CAL33, A431, 
OSC-19, and SCC1 are all epidermal cell lines lacking mutations that are known to confer 
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resistance to cetuximab, making them appropriate cell lines with which to develop resistance 
models. 
For these experiments, xenograft-bearing athymic nude mice were treated with increasing 
concentrations of cetuximab over the course of three months.  Animals were initially treated with 
moderate doses of cetuximab that are equivalent to four times that of a human dose (0.8mg twice 
weekly).  This was increased to doses equivalent to six times the standard human dose of 
cetuximab (0.8mg three times per week) over the course of three months.  A majority of the 
epithelial carcinoma-derived xenografts regressed with cetuximab treatment, including the head 
and neck cancer cell line SCC1 and its in vitro derived cetuximab resistant clone, SCC1c8 
(Figure 2-1A).  
While most xenografts treated with cetuximab were cetuximab-sensitive, four cetuximab-
resistant tumors (T24PR1-4) emerged out of the twelve original xenografts from T24 bladder 
carcinoma cells (Figure 2-1A).  Cetuximab-resistant tumors T24PR1-4 were surgically removed 
from sacrificed animals and digested into single cell suspensions that were used to generate cell 
lines of the same name in vitro and additional xenografts in vivo.  Xenografts from the 
cetuximab-resistant cells persisted despite treatment with doses of cetuximab equivalent to six 
times the human dose of cetuximab (0.8mg three times per week) immediately upon tumor 
formation (generally 7-10 days post-inoculation, Figure 2-1B).  The persistent growth of tumors 
derived from in vivo generated cetuximab-resistant cells as compared to in vitro generated 
cetuximab-resistant cells in high doses of cetuximab demonstrates the validity of in vivo 
generation for models of drug resistance, especially for therapeutic agents such as monoclonal 
antibodies that are known to have anti-tumor effects that cannot be reproduced under cell culture 
conditions. 
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Figure 2-1. Generation of a cetuximab-resistant bladder cancer model in vivo.  
A. T24, CAL33, A431, OSC-19, SCC1, and SCC1c8 cells were used to generate xenografts in athymic nude mice 
(n=6 for CAL33, A431, OSC-19, SCC1 and SCC1c8; n=12 for T24) that were exposed to increasing concentrations 
of cetuximab by i.p. injection (0.8mg 2x/week increased to 1.0mg 2x/week then increased to 0.8mg 3x/week; doses 
increased in non-responsive xenografts only as indicated by arrows).  Resistant tumor cells were then harvested and 
propagated in culture and B. re-inoculated to form xenografts that were treated with 0.8mg 3x/week immediately 
following tumor formation. 
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To distinguish acquired resistance to cetuximab from intrinsic resistance, we compared 
cetuximab sensitivity between the cetuximab-sensitive parental cells and the cetuximab-resistant 
clones.  To test this in vivo, athymic nude mice (n=7 mice) were inoculated with sensitive cells 
on one flank and resistant cells on another flank.  Following tumor formation, animals were 
randomized based on tumor volumes and treated with high concentrations of cetuximab (2.0mg 
three times per week).  Cetuximab-sensitive tumors demonstrated a 64.8% reduction in tumor 
volume on day 10 of cetuximab treatment compared to a 3.9-fold increase in cetuximab-resistant 
tumor volumes on day 10 of cetuximab treatment (p=0.002, Figure 2-2A).  Tumors were 
harvested after ten days of cetuximab treatment, frozen, fixed, cryosectioned and TUNEL-
stained to detect apoptotic cells.  61.7% of cells from cetuximab-sensitive tumors (T24) were 
apoptotic compared to only 26.3% of the cells from tumors derived from cetuximab resistant 
cells (T24PR3, Figure 2-2A, p=0.03).  These results demonstrate that by gradually increasing the 
dose of cetuximab in vivo over the course of 28 days, cetuximab resistant tumors can be 
generated. 
To demonstrate the differential cetuximab sensitivity of this model in vitro, we performed 
invasion assays since cetuximab does not inhibit proliferation in vitro[172].  Cetuximab has been 
previously reported by us and others to successfully decrease cell invasion through a Matrigel 
coated transwell-migration chamber[182, 183]. In this model, cetuximab decreased the invasion 
of parental T24 cells by 55.5% after 24 hours.  In contrast, cetuximab only inhibited the invasion 
of T24PR3 and T24PR4 cells by 1.7% (p=0.0009) and 8.7% (p=0.0001), respectively (Figure 
2-2B). 
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Figure 2-2. Validation of a cetuximab-resistant model in vitro & in vivo. 
A. Xenografts were generated by subcutaneous inoculation of one million tumor cells in athymic nude mice (n= 7) 
from cetuximab-sensitive T24 or cetuximab-resistant T24PR3 cells and treated with cetuximab (2.0mg 3x/week by 
i.p. injection) immediately following tumor formation, generally 7-10 days (**p<0.005).  TUNEL staining was 
performed on frozen, fixed tumors to detect apoptotic cells.  Data shown is the average of cells counted in 
quadruplicate 20X fields of view for two tumors per cell type (*p<0.05). B. Invasion studies were carried out with 
serum-free media containing either 1µM cetuximab or drug-free media.  Invasion chambers were placed in the same 
media containing 10% FBS.  After 24 hours, invading cells were stained and counted (**p<0.005). Data are the 
result of two independent experiments run in duplicate. 
 55 
It is worth noting that the T24 model has been previously reported to contain an Ha-Ras 
activating mutation[184].  Given the extensive evidence that K-Ras mutations confer resistance 
to cetuximab in colon cancer[148], the contribution of the H-Ras mutation to the cetuximab 
resistance mechanisms described in the present study remain unknown. To date, there is one 
published report based on in vitro work demonstrating that Ha-Ras is capable of conferring 
resistance to cetuximab by constitutively activating ERK and AKT[185].    While we believe this 
pathway is unlikely to contribute to the cetuximab resistance phenotype in vivo since the parental 
and the resistant cells are isogenic (both contain the mutation), we wanted to examine any 
differences in AKT phosphorylation between the sensitive and resistant cells.  No significant 
changes were observed in expression of basal or phosphorylated MAPK (not shown) or AKT 
(Figure 2-3) between the cetuximab sensitive and cetuximab resistant clones.  While T24PR4 
expressed slightly decreased levels of pAKT compared to T24 (p=0.513), T24PR3 expressed 
slightly increased pAKT compared to T24 (p=0.776).  Neither difference was statistically 
significant (Figure 2-3).  
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Figure 2-3. AKT is not overexpressed or hyperphosphorylated in cetuximab resistant cells. 
Cell lysates were collected under basal conditions when cells reached 70% confluence.  Whole cell lysates were 
analyzed by Western Blot and probed for p-AKT(Ser 403), AKT, and β-tubulin.  Densitometry is the result of three 
independent experiments where intensity of the p-AKT bands was compared to β-tubulin. 
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2.3.2 HNSCC Cell Lines are Highly Sensitive to Cetuximab 
Based on our success in generating a model of cetuximab resistance using bladder cancer 
cells, we attempted to generate models of cetuximab resistance using a similar approach in 
HNSCC cell lines.  Because our initial studies were conducted using a starting dose of cetuximab 
that is equivalent to four times the human dose of cetuximab (0.8mg twice weekly in Figure 
2-1A) and these studies only yielded resistant tumors from one cell line, we decided to decrease 
the starting dose of cetuximab to that of the therapeutic dose used in humans (0.2mg twice 
weekly).  To that end, we attempted to generate xenografts each from eight HNSCC cell lines: 
PCI-52, UM-22A, HN-5, 1483, CAL27, OSC-19, SCC1, SCC1c8 (n=6 xenografts per cell line).  
Each of these cell lines has been reported previously in the literature to form tumors in 
mice[176].  The SCC1c8 cell line is the reported model of cetuximab resistance generated in 
vitro from the HNSCC cell line SCC1[163], but this cell line was not resistant to cetuximab in 
our previous study (Figure 2-1). Nearly all inoculations produced tumors, with the exception of 
the PCI-52 cell line from which only one xenograft was established (Figure 2-4).   
Treatment was initiated when tumors were palpable (generally 7-14 days post-
inoculation) with lower doses of cetuximab (0.2mg twice per week) than were used previously 
(Figure 2-1) with the rationale that treating smaller tumors with lower doses of cetuximab would 
facilitate the selection of resistant tumor cells more effectively than in our previous study.  When 
treatment began, the median tumor volume was <40mm3 across all tumor types (Figure 2-4).  A 
summary of treatment schedules for the HNSCC cell line derived xenografts can be found in 
Table 2-1.  The vast majority of tumors responded to treatment with this low dose of cetuximab.  
We maintained cetuximab treatment for a total of 2-3 months for each cell line xenograft model 
to determine the incidence of spontaneous tumor recurrence as was observed for in vivo 
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generated models of trastuzumab resistance[180].  However, no HNSCC cell line xenograft 
recurrence was observed. 
Three tumors did demonstrate persistent growth in the presence of cetuximab treatment, 
one xenograft from the PCI-52 cell line (PCI-52A) and two xenografts from the OSC-19 cell line 
(OSC-19E & OSC-19F, Figure 2-4).  We were unable to isolate any epidermal cells in culture 
from the PCI-52A xenograft; only fibroblasts were grown from this tumor in culture and 
differential digestion methods were unsuccessful to remove contaminating fibroblasts.  Further, 
cells isolated in vitro from PCI-52A did not generate new xenografts when inoculated into 
another athymic nude mouse.  Likewise, cells from the OSC-19E tumor did not prorogate in 
culture or as a xenograft when inoculated into another athymic nude mouse.   Cells from OSC-
19F failed initially to grow in culture, but they did form another small xenograft that never 
exceeded 15mm3.  Efforts to propagate this secondary tumor were unsuccessful in culture or as 
another xenograft. 
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Cell 
Line 
Treatment 
Initiation 
Requirements 
Cetuximab Dose (mg) x 
Frequency (days per 
week) 
Total Amount of 
Cetuximab Per Week 
(mg) 
Days on 
Dose 
PCI-52 
Upon palpitation, 
generally 7-14 
days. Median 
tumor volume 
<40mm3. 
0.2x2 0.4 35 
UM-
22A 0.2x2 0.4 65 
CAL27 0.2x2 0.4 65 
HN-5 0.2x2 0.4 80 
1483 0.2x2 0.4 80 
OSC-19 0.2x2 0.4 80 
SCC1 0.2x2 0.4 49 
SCC1c8 0.2x2 0.4 49 
UM-22B Median tumor 
volume >50mm3. 
0.02x2 0.04 7 
0.04x5 0.2 14 
0.2x2 0.4 14 
CAL33 Median tumor 
volume >300mm3. 
0.02x2 0.04 7 
0.04x2 0.08 7 
0.08x2 0.16 14 
0.2x2 0.4 28 
Table 2-1. Summary of cetuximab dosing in HNSCC xenograft model generation. 
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Figure 2-4. HNSCC cell lines are sensitive to cetuximab at therapeutic doses in vivo. 
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Xenografts were created in nude mice from 8 HNSCC cell lines (PCI-52, UM-22A, CAL27, HN-5, 1483, OSC-19, 
SCC1, SCC1c8) using two million cells per inoculation.  Animals were treated with 0.2mg of cetuximab 2x/week by 
i.p. injection using, for 7-11 weeks as indicated.  Treatment was initiated upon tumor palpitation, generally 7-14 
days following inoculation.  Median tumor volume at the start of treatment is less than 40mm3 for all cell lines. 
 
Because these attempts at model generation were unsuccessful, we altered our 
methodology to include larger starting tumor volumes and lower doses of cetuximab.  We 
attempted to generate cetuximab resistant xenografts using the UM-22B cell line with these 
modified conditions.  We generated six xenografts using UM-22B cells, and we did not begin 
treatment of the animals until the median tumor volume exceeded 50mm3 (Figure 2-5A).  We 
also used a sub-therapeutic dose of cetuximab for initial treatment.  A summary of the treatment 
regimen used in this experiment can be found in Table 2-1.  The animals were treated initially 
with approximately one-tenth the therapeutic dose of cetuximab, administered as 0.02mg twice 
weekly by i.p. injection.  The xenografts did not respond to cetuximab at this dose during the 
first week of treatment.  We then increased the dose of cetuximab to 0.04mg five times per week.  
There was a mixed response to this sub-therapeutic dose, but after two weeks at this dose no 
tumors had regressed completely (Figure 2-5A).  Finally, we increased treatments to the 
therapeutic dose of cetuximab, 0.2mg twice per week.  All tumors had dramatic responses to this 
dose of cetuximab (Figure 2-5A) but tumor regression was delayed by up to 14 days in UM-22B-
derived xenografts (Figure 2-5A) compared with the other HNSCC cell line xenografts (Figure 
2-4), suggesting that larger tumor volumes and sub-therapeutic doses of cetuximab may facilitate 
the selection of cetuximab-resistant cells.   
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 In order to enhance the selection of cetuximab-resistant cells, we further increased tumor 
starting volumes and the amount of time during which animals were treated with sub-therapeutic 
doses of cetuximab.  We did not begin treatment on the CAL33 xenografts until the median 
tumor volume exceeded 300mm3.  One xenograft (CAL33F) was nearly 600mm3 when treatment 
began (Figure 2-5B).  Further, we allowed four weeks of sub-therapeutic cetuximab 
administration to mice harboring CAL33-derived xenografts.     
During the first seven days on treatment, animals with xenografts from CAL33 cells 
received 0.02mg of cetuximab twice weekly.  No tumors responded to treatment at this dose.  
During days 7-14 of treatment, animals received 0.04mg of cetuximab twice weekly.  No tumors 
responded to this dose of cetuximab.  Animals were then given 0.8mg of cetuximab twice 
weekly during days 14-28 of treatment.  During this two-week period, we observed dramatic 
reductions in tumor volume for all xenografts (Figure 2-5B).  Following this month of treatment 
at sub-therapeutic doses, we treated animals with a therapeutic dose of cetuximab, 0.2mg twice 
weekly for an additional month.  During this time, all tumors regressed but one tumor 
subsequently had spontaneous re-growth (CAL33B, Figure 2-5B).  A summary of the treatment 
regimen used in this experiment can be found in Table 2-1. 
To determine if this spontaneous re-growth was indicative of acquired cetuximab 
resistance, the CAL33B tumor was disaggregated and grown under cetuximab selection pressure 
in vitro.  This cell strain is called CAL33AR1.  Equal numbers of CAL33AR1 and CAL33 
parental cells were used to generate xenografts in athymic nude mice (n=5 per cell line).  Once 
tumor volumes exceeded 50mm3, animals were treated with 0.2mg of cetuximab twice weekly 
for two weeks.  After 15 days, no significant differences in tumor volumes were observed 
(Figure 2-5C), suggesting that this model of cetuximab resistance is not reproducible.    
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Figure 2-5. HNSCC cell lines are sensitive to cetuximab at sub-therapeutic doses in vivo. 
A. Xenografts were created in nude mice from UM-22B cells using two million cells per inoculation.  Treatment 
was initiated when tumors reached a median tumor volume of approximately 50mm3, generally 7-14 days post 
inoculation.  Animals received cetuximab as 0.02mg 2x/week by i.p. injection. After one week of treatment (dashed 
line) the dose was increased to 0.4mg 5x/week for two weeks and then raised to 0.2mg 2x/week (dashed line).   B.  
Xenografts were created in nude mice from CAL33 cells using two million cells per inoculation.  Treatment was 
initiated when tumors reached a median tumor volume of approximately 300mm3, generally 7-14 days post 
inoculation.  Animals initially received cetuximab as 0.02mg 2x/week by i.p. injection.  After one week of treatment 
(dashed line), the dose was increased to 0.04mg 2x/week.  After another week (dashed line), the dose was increased 
to 0.08mg 2x/week.  After two more weeks (dashed line) the animals began one month of treatment at the 
therapeutic dose, 0.2mg 2x/week. C.  Xenografts were created in nude mice from the resistant CAL33 tumor cell 
line (Cal33AR1) and the parental CAL33 cell line (n=5 tumors per cell line).  Two million cells were used per 
inoculation, and animals were treated once median tumor volume reached 50mm3.  Animals were treated for two 
weeks with the therapeutic dose of cetuximab, 0.2mg 2x/week.  No significant differences were observed in tumor 
volumes (p=0.732). 
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2.3.3 HNSCC Heterotopic Tumorgrafts May Serve as Models of Cetuximab Resistance 
Data suggests that therapeutic results in preclinical cell line xenograft models of cancer 
may not accurately predict for human response to the same agents[186].  A more translational 
model system that is recognized as more representative of human response to anti-cancer agents 
is “ex”plant xenografts, or tumor grafts[187, 188].  This model is sometimes also referred to as 
heterotopic xenografts.  Tumorgrafts are tumors that are surgically transplanted directly from 
human patients into severe combined immunodeficiency (SCID) mice.  Mice bearing the SCID 
mutation have impaired T and B cell lymphocytes, as compared to the immunocompromised 
athymic nude mice that lack only T cells.  The combined immunodeficiency of SCID mice 
provides enhanced abrogation of the immune system compared to nude mice. 
 Because our attempts to generate cetuximab resistance models with HNSCC cell lines in 
nude mice were not reproducible, we next attempted to generate cetuximab resistance models 
with HNSCC tumorgrafts.  The work in this section was performed with Dr. Sarah Wheeler, a 
collaborator in our laboratory.  Dr. Wheeler performed all the animal surgeries and was 
responsible for some treatments and measurements.  Kelly Quesnelle crafted the experimental 
design, performed the majority of treatments and measurements and performed all data analysis.  
Tumorgrafts from three HNSCC patient tumors were created by implanting approximately 
25mm of each human tumor into the flanks of anesthetized SCID mice.  Once tumor volume 
reached 50mm3, animals were treated with sub-therapeutic doses of cetuximab (0.02mg twice 
weekly).  All tumors progressed at these doses to the maximum allowable tumor volume under 
IACUC guidelines.  Once maximum tumor volume was reached, tumorgrafts were passaged into 
new SCID mice and the dose of cetuximab was increased with each subsequent passage of the 
tumors.  During the third passage of these tumorgrafts, we started treatment at a sub-therapeutic 
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dose of cetuximab (0.08mg twice weekly) and increased to the therapeutic dose of cetuximab 
(0.2mg twice weekly) in non-responsive tumorgrafts.  A summary of this treatment can be found 
in Table 2-2. 
 We created tumorgrafts from three HNSCC patient tumors, identified as 11-6031, 11-
5845, 11-5822 and at least 30% of tumorgrafts from each patient tumor demonstrated growth in 
the presence of therapeutic doses of cetuximab (0.2mg twice weekly, Table 2-2).  From the 11-
6031 tumor, 2/2 tumorgrafts (100%) demonstrated growth during treatment with 0.2mg of 
cetuximab twice weekly.  The final volume of these tumorgrafts after 18 days of treatment was 
240% greater, on average, than their starting volumes.  From the 11-5845 tumor, 11/15 
tumorgrafts (73%) demonstrated growth during treatment with 0.2mg of cetuximab twice 
weekly.   The final volume of these 11 tumorgrafts after an average of 14 days on treatment was 
a 270% increase, on average, relative to the starting tumor volumes.  From the 11-5822 tumor, 
5/16 tumorgrafts (31%) demonstrated growth during treatment with the therapeutic dose of 
cetuximab, 0.2mg twice weekly.  The final volume of these 5 tumorgrafts after an average of 16 
days on treatment was a 89% increase, on average, relative to the starting tumor volumes.  These 
rates of resistance (31-100%) are much more representative of HNSCC patient response rates to 
cetuximab, suggesting the relevance of tumorgrafts for modeling cetuximab resistance. 
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Table 2-2. Response rates of HNSCC explants xenografts to cetuximab 
Heterotopic xenografts generated from three unique HNSCC patient tumors demonstrated selection to cetuximab at 
subtherapeutic doses (0.08mg 2x/week) of cetuximab.  Xenografts that did not regress more than 50% under these 
conditions were increased to  a therapeutic dose of cetuximab (0.2mg 2x/week).  Starting and ending tumor volumes 
for 36 heterotopic xenografts are shown here.  Data shown is in collaboration with Dr. Sarah Wheeler. 
HN 
Identifier
Xenograft 
Identifier
Initial Tumor 
Volume 
(mm3)
Final Tumor 
Volume 
(mm3)
Days of 
Cetuximab 
Treatment
Biweekly dose 
of cetuximab 
(mg)
Change in 
Tumor 
Volume (%)
11-6031 442.R1.1L 334.35 1058.25 18 0.08-0.2 217%
442.R1.1R 240.28 873.38 18 0.08-0.2 263%
11-5845 210.R1.1.1L 108.46 418.12 19 0.08-0.2 286%
210.R1.1.1R 76.70 467.74 19 0.08-0.2 510%
210.R1.4.1R 209.19 212.95 19 0.08-0.2 2%
210.R1.4.1L did not grow did not grow 19 0.08-0.2 n.a.
210.R1.4.2L 71.68 0.00 8 0.08-0.2 -100%
210.R1.4.2R 74.39 89.10 8 0.08-0.2 20%
210.R1.2.2L 160.38 708.66 15 0.08-0.2 342%
210.R1.2.2R 0.00 203.84 15 0.08-0.2 204%
210.R2.4.1L 51.72 0.00 12 0.08-0.2 -100%
210.R2.4.1R 75.40 89.10 12 0.08-0.2 18%
210.R2.2.1L 47.31 0.00 8 0.08-0.2 -100%
210.R2.2.1R 36.68 0.00 8 0.08-0.2 -100%
210.R2.4.2L 0 104.37 12 0.08-0.2 104%
210.R2.4.2R 224.45 2982.1 12 0.08-0.2 1229%
210.R2.2.2L 0 91 12 0.08-0.2 91%
210.R2.2.2R 94.94 250.58 12 0.08-0.2 164%
11-5822 197.R3.2.2L did not grow did not grow 17 0.08-0.2 n.a.
197.R3.2.2R 146.96 334.34 17 0.08-0.2 128%
197.R3.1.2L 138.53 102.24 21 0.08-0.2 -26%
197.R3.1.2R 48.1 81.55 21 0.08-0.2 70%
197.R2.1.1L 80.36 64.7 14 0.08-0.2 -19%
197.R2.1.1R 57.92 132.95 14 0.08-0.2 130%
197.R2.2.1L 136.66 91.4 14 0.08-0.2 -33%
197.R2.2.1R 170.39 151.76 14 0.08-0.2 -11%
197.R2.2.2L 519.38 962.78 14 0.08-0.2 85%
197.R2.2.2R 366.58 484.38 14 0.08-0.2 32%
197.R3.1.1L 193.97 59.73 22 0.08 -69%
197.R3.1.1R 288.34 74.91 22 0.08 -74%
197.R2.1.2L did not grow did not grow 12 0.08 n.a.
197.R2.1.2R 116.4 7.3 12 0.08 -94%
197.R2.3.1L 559.33 27.05 14 0.08 -95%
197.R2.3.1R 316.16 83.2 14 0.08 -74%
197.R2.3.2L 399.98 50.34 14 0.08 -87%
197.R2.3.2R 71.17 34.11 14 0.08 -52%
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2.3.4 HNSCC Cell Lines Have a Narrow Range of Sensitivity to Erlotinib 
Unlike cetuximab models of resistance in HNSCC, preclinical models of acquired 
resistance to erlotinib are more widespread[158, 161].  We received the previously published 
isogenic cell pair consisting of the HNSCC cell line 686LN and its EGFR TKI resistant 
subclone, 686LNR30, from Dr. Georgia Chen (Emory University)[161].  Cellular genotyping to 
confirm the isogenicity of these cell lines determined that the resistant subclone was not an 
HNSCC cell line but rather a type of cervical cancer cell line, HeLa.  This mislabeling left us 
without an isogenic model of acquired resistance to erlotinib.  However, because most primary 
tumors in HNSCC are resistant to erlotinib treatment, we chose to focus our studies on models of 
primary resistance in HNSCC.  We determined response to erlotinib across a panel of HNSCC 
cell lines, rather than relying on one cell model, with the goal of identifying primary resistance to 
erlotinib in HNSCC. 
We performed cell viability assays on a panel of eight HNSCC cell lines after 72 hours of 
growth in the presence of erlotinib or vehicle control to determine erlotinib sensitivity.   There 
was a narrow range of erlotinib IC50s from 1.56µM (HN-5) to 6.6µM (UM-22A, Figure 2-6).  
Because all of these HNSCC cell lines have IC50s to erlotinib below 10µM, we included HeLa 
cells as an erlotinib-resistant control (IC50=44.60µM).  The narrow range of IC50s to erlotinib in 
HNSCC cell lines, coupled with the scarcity of information regarding intratumoral erlotinib 
concentrations in head and neck cancer, makes it highly subjective to delineate sensitivity versus 
resistance based on these in vitro data. 
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Figure 2-6. HNSCC cells have a narrow range of sensitivity to erlotinib. 
A panel of 8 HNSCC cell lines (HN-5, PCI-15B, 686LN, OSC-19, UM-22B, SCC1, CAL33, UM-22A) were treated 
in triplicate with erlotinib for 72 hours followed by MTT assay. Relative IC50s were calculated from three 
independent experiments.  IC50 values range from 1.56µM to 6.6µM in HNSCC cell lines.  HeLa cells were used as 
a control to demonstrate in vitro resistance to erlotinib (IC50=44.60µM). 
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To determine erlotinib sensitivity in vivo, we used 686LN as a representative HNSCC 
cell line since the range of sensitivities to erlotinib is relatively narrow.  We have shown 
previously that 686LN cells are sensitive to cetuximab in vivo (Figure 2-4), so we used these as a 
control to establish HeLa cells as an EGFR-inhibitor resistant model in vivo (Figure 2-7A).  Nine 
mice were inoculated with equal numbers of 686LN and HeLa cells on opposite flanks and we 
observed a significant difference in tumor volumes following 10 days of cetuximab treatment 
(p=0.0013).  HeLa cells are not sensitive to cetuximab in vivo, while 686LN cells are sensitive to 
cetuximab in vivo.  In line with this, we used HeLa cells as an erlotinib-resistant control to test 
the sensitivity of 686LN cells to erlotinib in vivo.  Following 10 days of erlotinib treatment, there 
is also a significant difference in tumor volumes between 686LN and HeLa cells (p=0.0036) 
(Figure 2-7B).  These data demonstrate that 686LN cells are sensitive to EGFR inhibition in 
vivo, while HeLa cells are not. 
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Figure 2-7. 686LN cells are sensitive to erlotinib in vivo. 
A. 686LN cells and HeLa cells are differentially sensitive to cetuximab in vivo. The 686LN cell line was used to 
create xenografts in nude mice from one million cells per xenograft with Matrigel (n=9).  HeLa cells were used as a 
cetuximab-resistant control at a rate of one million cells per inoculation to create xenografts (n=9).  Animals were 
treated with a higher than therapeutic dose of cetuximab, 1.0mg 2x/week, by intraperitoneal injection and a 
significant difference in tumor volumes was observed between the two cell lines on day 10 (p=0.0013).  B. The 
HNSCC cell line 686LN was used to create xenografts in nude mice from one million cells per xenograft with 
Matrigel (n=9).  HeLa cells were used as an erlotinib-resistant control at a rate of one million cells per inoculation to 
create erlotinib-resistant control xenografts (n=9).  Animals were treated with 50mg/kg erlotinib five times per week 
by oral gavage and a significant difference in tumor volumes was observed between the two cell lines on day 10 
(p=0.0036).   
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2.3.5 Sensitivity to EGFR Inhibitors Correlates with EGFR Protein Levels 
High EGFR levels have been reported to correlate with improved responses to erlotinib in 
head and neck cancer and non-small cell lung cancer patients[70, 189-192]. This suggests that 
erlotinib-resistant cells may not be dependent on EGFR signaling.  To test this in our models, we 
first determined the cell surface levels of EGFR in 686LN cells, which we have shown to be 
sensitive to both erlotinib and cetuximab in vitro and in vivo, and in HeLa cells, which we have 
shown to be resistant to both erlotinib and cetuximab in vitro and in vivo.  As has been reported 
in HNSCC patients, we detected a lower number of EGFR-negative cells in 686LN versus HeLa 
(0.20±0.01% for 686LN cells and 14.85±0.24% for HeLa cells, Figure 2-8A). 
We attempted to extrapolate this finding to our panel of eight HNSCC cell lines by 
assessing EGFR protein expression levels from whole cell lysates (Figure 2-8B).  A Spearman 
correlation analysis of immunoblot densitometry from three representative experiments showed a 
statistically significant correlation between EGFR protein level and erlotinib response in vitro 
(r=-0.8333, p=.0154). 
Data from recent trials in NSCLC suggests that high EGFR expression correlates with 
response to cetuximab, in accordance with similar observations for erlotinib[193].  In HNSCC, 
one study has examined EGFR copy number and found no associations with cetuximab response, 
although protein levels of EGFR were not assessed in this study[194].  Consistent with other in 
vitro studies of cetuximab resistance[195], we found that EGFR was downregulated in 
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cetuximab-resistant T24PR3 and T24PR4 cells compared to the isogenic parental T24 cells 
(Figure 2-8C). 
 
Figure 2-8. EGFR protein levels correlate with sensitivity to EGFR inhibitors. 
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A.  686LN cells have higher levels of EGFR on the cell surface compared to the EGFR-inhibitor resistant HeLa cell 
line.  Live cell sorting was used on 686LN cells and HeLa cells with gating to exclude cells that uptake propidium 
iodine and to identify a population of low-EGFR expressing cells (0.20±0.01% for 686LN cells and 14.85±0.24% 
for HeLa cells).  B.  EGFR expression correlates with erlotinib sensitivity in HNSCC cells.  Whole cell lysates were 
created from cells plated at 70% confluency in standard media and proteins were resolved and immunostained (α-
EGFR, BD Transduction Labs).  Densitometry was calculated as an average from three independent experiments. C.  
EGFR levels are reduced in cetuximab resistant cell models T24PR3 and T24PR4 compared to cetuximab sensitive 
T24 parental cells.  Whole cell lysates were created from cells plated at 70% confluency in standard media and 
proteins were resolved and immunostained (α-EGFR, BD Transduction Labs). 
 
2.4 DISCUSSION 
Acquired resistance to cetuximab is an important clinical problem in cancer patients 
treated with this FDA-approved EGFR monoclonal antibody. Elucidation of the mechanisms of 
acquired resistance has been limited by the paucity of preclinical models.  The T24 model of 
cetuximab resistant bladder cancer presented in the current study was generated in vivo and 
shown to be statistically significant in vivo across several doses of cetuximab, including 1.0mg 
three times per week and 2.0mg three times per week.  These more robust dosing schedules were 
chosen because they are higher than the therapeutic human dose, they are used widely by others 
in the literature[77, 196], and doses greater than 0.25mg three times per week have been 
previously identified as the optimal therapeutic doses of cetuximab in pharmacokinetic studies 
using mice[197]. Further, one group initially reported in vitro generated models of trastuzumab 
resistance and subsequently reported that these models were not reproducible in vivo, suggesting 
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that in vitro generated models of antibody-resistance may not extend to in vivo settings and 
underscoring the importance of generating models of resistance to biological therapeutics in 
vivo[198]. 
The T24 model presented here could be used to study the anti-tumor effects of ADCC in 
vivo in the future in addition to the other mechanisms already described here.  The athymic nude 
mouse model used in these experiments could be used to study ADCC, as others have knocked 
out the FCγR (Immunoglobulin G Fc Receptor II found on NK cells, responsible for ADCC 
response) in nude mice and showed reduced anti-tumor effects of human IgG1 backbone 
antibodies in the FCγR -/- compared to FCγR +/+ mice in the setting of treatment with 
trastuzumab and rituximab which share the same IgG1 human backbone as cetuximab that is 
responsible for binding the FCγR and initiating ADCC[199].   
Our attempts to generate models of resistance using genotypically validated HNSCC cell 
lines were unsuccessful across all ten cell lines.  Alterations in tumor size and cetuximab dose 
were all performed in attempts to optimize the conditions under which resistant models may be 
generated.  Unfortunately, none of these alterations managed to yield a cell line that was less 
sensitive to cetuximab than the original parental cell line from which they were generated.   
Literature has shown that tumor size correlates with decreased sensitivity to 
chemotherapy and EGFR inhibitor response in mice[200, 201].  Gross tumor volume also 
correlates with worse outcome for head and neck cancer patients receiving cetuximab with 
radiation[202].  We hypothesized that increasing tumor size may decrease the responsiveness of 
tumors to cetuximab.  Our data did not support this hypothesis, however, since even greater than 
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10-fold increases in tumor volume did not seem to affect response to cetuximab in the HNSCC 
cell line xenografts (Figure 2-4 and Figure 2-5). 
The T24 model was successfully generated using xenografts created from one million 
cancer cells inoculated with Matrigel (BD Biosciences) (Figure 2-1).  Subsequent animal studies 
(Figure 2-4 and Figure 2-5) were unsuccessful at generating models of cetuximab resistance and 
these xenografts were generated using two million cancer cells without the presence of Matrigel.  
Matrigel is a basement membrane milieu comprised of laminin, collagen IV, heparan sulfate 
proteoglycan, nidogen and entactin[203, 204].    Matrigel, and, more specifically, laminin can 
dramatically increase the malignant phenotype of cell lines by increasing invasiveness, tumor 
volume, adhesion, migration, and collagenase IV activity (which increases invasion)[205-207].  
There is also evidence to suggest that Matrigel can increase resistance to cytotoxic drugs in 
vitro[208].  It is not known to what extent the inclusion of Matrigel may have altered the tumor 
microenvironment and contributed to the generation of the T24 model, or to what extent the 
absence of Matrigel inhibited the development of HNSCC resistant tumors.  Our data does show 
that exclusion of Matrigel did not alter the sensitivity of 686LN cells to cetuximab, though, 
suggesting that the contribution of Matrigel to inhibitor resistance is minimal, if any. 
We were met with more success generating resistance models using the explant xenograft 
model from human tumor tissues.  Our efforts at generating cell strains from these tumorgrafts 
have been unsuccessful to date, but the fact that between 30% and 100% of tumorgrafts are 
resistant to cetuximab is much more representative of human response rates to cetuximab than 
our cell line xenograft results.  There was a range of tumorgraft response rates to cetuximab at 
the therapeutic dose that was highly variable across the three patient tumors (0%, 27%, and 69% 
for our three tumors).  While these are interesting data that may correlate with variations in 
 77 
patient response or molecular pathogenesis determinants such as the presence of HPV or 
EGFRvIII, our sample size in the current study is too limited to perform these types of 
correlations.  In the current study, we have presented a novel way to generate cetuximab resistant 
models and given preliminary evidence that larger sample sizes are warranted for future studies 
in which clinical correlations can be addressed. 
Defining primary resistance to erlotinib is challenging because the physiological 
concentration of intratumoral erlotinib is not well studied in HNSCC.  The maximum plasma 
concentration, Cmax, of erlotinib in cancer patients receiving the standard oral dose of 150mg/day 
has been reported in non-smokers as 950ng/mL (2.45µmol/L) and in smokers as 1055ng/mL 
(2.2µmol/L)[209].  A study using 11C-labeled erlotinib to detect tissue distribution of erlotinib in 
mice with lung cancer xenografts has suggested that erlotinib concentrations in the tumor can be 
up to four-fold higher than blood concentrations.  This effect is correlated with erlotinib 
sensitivity, i.e. erlotinib-sensitive tumors can have up to four-fold higher intratumoral erlotinib 
concentrations where erlotinib-resistant tumors have intratumoral erlotinib concentrations similar 
to those of the blood[210].  One study has reported clinical concentrations of intratumoral 
erlotinib in aerodigestive tract tumors.  This study corroborates the preclinical findings and 
reports higher intratumoral erlotinib concentrations in patients who responded to erlotinib 
treatment.  Erlotinib-responding tumors had intratumoral erlotinib concentrations of 4.1µM and 
4.8µM, where erlotinib-resistant tumors had lower intratumoral erlotinib concentrations, 1.7µM 
and 0.3µM[211].  This suggests that concentrations higher than the maximum blood plasma 
concentration are achievable intratumorally in erlotinib-sensitive tumor tissues, but studies 
examining this in large cohorts of patients have not yet been reported.   
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We examined EGFR expression levels in our cell lines and found that total levels of 
EGFR protein correlate with EGFR inhibitor sensitivity (Figure 2-8B). Reduced levels of EGFR 
at the cell surface is thought to play a role in both erlotinib and cetuximab resistance[212, 213], 
and here we observed decreased EGFR levels both on the cell surface and in the whole cell 
lysates of EGFR inhibitor resistant cells.  Importantly, our data contrasts with one report of 
clinical erlotinib use in HNSCC where EGFR protein levels are not indicative of erlotinib 
response[113].  While this does not negate our hypothesis that EGFR inhibitor resistant tumors 
are driven by EGFR-independent growth, it does speak to the disconnect between preclinical and 
clinical observations. 
In conclusion, we have examined antitumor responses to cetuximab using a panel of 
HNSCC cell line xenografts as well as tumorgrafts from human tumor tissues.  In accordance 
with the literature, we find that tumorgrafts are potentially more representative of patient 
response to cetuximab than HNSCC cell line xenografts.  We did, however, successfully 
generate and validate a novel in vivo model of cetuximab resistance using a bladder cancer cell 
line.  This model can be used to study mechanisms of resistance to cetuximab.   
In order to create a model with which to study erlotinib sensitivity, we determined the 
response of a panel of HNSCC cell lines to erlotinib and correlated this sensitivity with EGFR 
expression levels.  These data provide a thorough and descriptive study of preclinical modeling 
of EGFR inhibitor resistance in HNSCC and can serve as a guideline for future studies using 
these models.  Taken together, these findings demonstrate the need for development of additional 
preclinical models of cetuximab resistance and provide a platform by which to examine 
mechanisms of resistance to EGFR targeting agents.  
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3.0  KINASE INHIBITION OF HER2 AND EGFR CAN OVERCOME RESISTANCE 
TO AN EGFR-TARGETING ANTIBODY 
3.1 INTRODUCTION 
In the absence of genomic mutations in KRAS or EGFR, no definitive signaling 
mechanism is known to confer resistance to the EGFR inhibitor cetuximab.  Alternative 
signaling through HER2, HER3, and c-Met have all been implicated in cetuximab resistance.  
Combined with our finding that cetuximab-resistant bladder cancer cells have reduced levels of 
EGFR (Figure 2-8C), signaling through HER2, HER3, and c-Met may provide a viable means 
for EGFR-independent cell growth in these cells. 
3.1.1 HER2 and HER3 Signaling in Cetuximab Resistance 
One possible mechanism of cetuximab resistance may involve redundant signaling 
through other ErbB family members (HER re-programming), including HER2 and HER3.  Co-
expression of multiple ErbB family members is more predictive of shortened survival than 
expression of EGFR alone in some cancers[55] and co-activation of EGFR with HER2 has been 
implicated in resistance to trastuzumab, a HER2-targeting agent, in breast cancer models[180].  
EGFR is also shown to be upregulated after long term exposure to trastuzumab[214], further 
reinforcing the critical nature of these redundant pathways to cellular growth in malignancies. 
Blockade of HER2 or HER3 has been shown to re-sensitize lung cancer cells to cetuximab in 
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vitro[163], likely because HER2 and HER3 signaling occurs through many of the same 
downstream effectors as EGFR, including MAPK and PI3K[215].  HER2 gene amplification has 
also been found in lung cancer patients with acquired or de novo cetuximab resistance[98].  
Further, it is known that HER3 can compensate for inhibition of EGFR and HER2 in breast 
cancer models[216].  Taken together, these data suggest that HER2 or HER3 signaling may serve 
as a mechanism of growth in cetuximab resistant tumor cells. 
3.1.2 C-Met Signaling in Cetuximab Resistance 
Like the other ErbB family members, c-Met signals through many of the same 
downstream pathways as EGFR including MAPK and PI3K and is even capable of activating 
EGFR and HER3 for signaling[217].  It is known that c-Met amplification is a key mechanism of 
acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer (Paragraph 1.3.3), but data 
implicating c-Met in cetuximab resistance are rare.  c-Met activation has been implicated in 
preclinical models of cetuximab resistance in gastric cancer[167].  Additionally, c-Met protein 
expression correlates with decreased progression-free survival in colon cancer patients who have 
been treated with cetuximab[218], suggesting that c-Met may play a role in cetuximab resistance. 
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3.2 MATERIALS AND METHODS 
3.2.1 Cells and Reagents 
SCC1 was derived from a primary HNSCC tumor and both SCC1 and the cetuximab-
resistant clone SCC1c8 were maintained in DMEM with 10% FBS and 0.4ug/mL hydrocortisone 
[163]. OSC-19 cells were maintained in MEM with 10% FBS and 1% non-essential amino acids.  
CAL33, T24, and A431 cells were maintained in DMEM + 10% FBS.  All cell lines were 
validated by genotyping within 6 months of their use using the AmpFISTR Identifiler System 
(Applied Biosystems).  Cetuximab-resistant clones were maintained in media with 100nM 
cetuximab.  Cetuximab (Erbitux, ImClone Systems and Bristol-Myers Squibb) was purchased 
from the University of Pittsburgh Pharmacy. Afatinib was obtained from Boehringer Ingelheim 
as a powder and resuspended in DMSO for in vitro studies or 0.5% methylcellulose with 0.4% 
tween 80 in saline for animal studies. Trastuzumab (Herceptin, Genentech) was purchased from 
the University of Pittsburgh Pharmacy and diluted as recommended in the package insert.  
Erlotinib was purchased from Chemietek and dissolved in DMSO for in vitro studies. 
3.2.2 Combination Treatment Animal Study 
Two million parental and resistant cells were injected on opposite flanks of the same 
mouse (n=40) with Matrigel and animals were stratified by tumor volume[219] into four groups 
then randomly distributed from each group into four treatment groups with ten animals per 
group.  Animals were treated with cetuximab, afatinib, or both. The treatments and 
measurements were performed by an individual blinded to the treatment. 1.0mg of cetuximab or 
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vehicle control was given by i.p. injection three times per week by and 0.4mg afatinib or vehicle 
control was given daily by oral gavage.   
3.2.3 Invasion Assays 
Five thousand cells were plated in the inner well of a Matrigel Invasion Chamber (BD 
Biosciences) in serum free-media. Wells were placed into media containing 10% FBS and drugs 
were added to both chambers where indicated.  After 24 hours, cells invading through the 
Matrigel coated membrane were stained and counted.   
3.2.4 Immunoblotting 
Immunoblots were performed on 70% confluent cell lysates after plating in drug-free 
media.  Lysates were resolved on SDS-PAGE gels and transferred to nitrocellulose membranes 
prior to antibody staining with the following antibodies: HER2 and 611-CTF, (clone F11, sc-
7301) Santa Cruz; pHER2 and 611-CTF, Y1248 (2247s) Cell Signaling; pSerine, BD 
Transduction Labs; Cortactin, Upstate Biotechnology; c-Met, Santa Cruz; p-c-Met (Y1234/5), 
Cell Signaling; HER3 and p-HER3 (Y1289), Cell Signaling.  Densitometry was performed using 
Image J software. 
3.2.5 shRNA Experiments 
Lentiviral particles were provided by Dr. R.W. Sobol and the University of Pittsburgh 
Cancer Institute (UPCI) Lentiviral Facility. Virus stocks were generated by co-transfection of the 
shRNA expression plasmid (pLK0.1; Mission shRNA library from Sigma) into 293-FT cells 
together with the packaging plasmids pMD2.g (VSVG), pRSV-REV, pMDLg/pRRE. Forty-eight 
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hours post transfection viral particles were collected in the culture supernatant, filtered (0.45 
µM) and stored at -80˚C or used immediately to transduce the target cells. 
3.2.6 Metabolic Activity Assays 
Cells were plated at a density of 30,000 cells per well in 24-well plates to achieve a 
density approximately 50% confluent.  Cells were treated the following day with vehicle control 
(0.05% DMSO) or various concentrations of erlotinib or afatinib (250nm-50µM).  After 72 
hours, media was replaced with 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) for 30 minutes.  Cells were then washed with PBS and DMSO was added to dissolve the 
purple reduction product of MTT, formazan.  Formazan containing DMSO was read on the 
spectrophotometer at 540nm and compared to vehicle controls to determine level of cell 
viability. 
3.2.7 Statistical Analyses 
Erlotinib and afatinib relative IC50 with associated 95% confidence intervals were 
calculated using GraphPad Prism v5.0. The nonlinear regression curves for erlotinib and afatinib 
response had R2 values greater than 0.70.  P-values were generated for the combination treatment 
animal study using a Mann-Whitney test for non-parametric data.  P-values were generated for 
invasion assays using a homoscedastic two-tailed Student’s t-Test.  Statistical analyses for 
immunoblots were conducted using homoscedastic student’s t-tests. 
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3.3 RESULTS 
3.3.1 HER3 is Not Differentially Expressed or Phosphorylated in the Cetuximab 
Resistance Model 
We used a candidate-based approach to explore differences in the cetuximab-sensitive 
and cetuximab-resistant cells, focusing primarily on the expression and phosphorylation of c-Met 
and the ErbB family members.    HER3 was expressed at low levels in T24, T24PR3, and 
T24PR4 clones, and we observed no significant difference in expression of total or 
phosphorylated levels of HER3 across these cell lines (Figure 3-1).   
 
Figure 3-1. HER3 is unchanged in cetuximab resistant cells. 
Cell lysates were collected under basal conditions when cells reached 70% confluence.  Whole lysates were 
analyzed by Western Blot and probed for HER3 and pHER3(Y1289, Cell Signaling). 
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3.3.2 C-Met Contains a Polymorphism and Is Not Differentially Expressed or 
Phosphorylated at Y1234/5 in the Cetuximab Resistance Model 
Mutational analysis of the T24 cell line identified a T1010I mutation in the c-Met 
receptor.  While this was originally thought to be an oncogenic mutation[220], newer and more 
comprehensive data suggests that this is merely a normal polymorphism[221].  Here, we 
examined the basal expression and phosphorylation of c-Met in our cetuximab sensitive (T24) 
and cetuximab resistant (T24PR3, T24PR4) cells, and found no significant difference between 
basal levels of c-Met protein expression or phosphorylation at Tyr1234/5 across cetuximab 
sensitivity and resistant cells (Figure 3-2). 
 
Figure 3-2. c-Met is not differentially expressed or phosphorylated in cetuximab resistance model. 
Cell lysates were collected under basal conditions when cells reached 70% confluence.  Whole lysates were 
analyzed by Western Blot and probed for c-Met(Santa Cruz) and pMet(Y1234/5, Cell Signaling). 
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3.3.3 Cetuximab-Resistant Cells Express a Hyperphosphorylated Form of 611-CTF, a 
Carboxyl-Terminal HER2 Fragment 
While there was no significant change in the expression or phosphorylation at Tyr1248 of 
full length HER2 among cetuximab-sensitive and cetuximab–resistant cells, we did observe a 
significant increase in phosphorylation of 611-CTF, a carboxyl-terminal fragment of HER2, in 
only the cetuximab resistant cells (Figure 3-3).  Despite the abundance of total 611-CTF protein 
in T24, T24PR3 and T24PR4 and other cells, 611-CTF appears to be phosphorylated at Tyr1248, 
the site responsible for MAPK activation, in only the cetuximab resistant clones, T24PR3 and 
T24PR4.  Densitometry confirms T24PR3 and T24PR4 cells to significantly express 
phosphorylated 611-CTF at levels 5.6 (p=0.0223) and 5.9 (p=0.0309) fold higher, respectively, 
than T24 cells (Figure 3-3).   
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Figure 3-3. Expression of hyperphosphorylated 611-CTF protein in cetuximab-resistant cells. 
Cell lysates were collected under basal conditions when cells reached 70% confluence.  Whole lysates were 
analyzed by Western Blot and probed for HER2 and pHER2 (185 kDa), 611-CTF and p611-CTF (110 kDa HER2 
fragment).  Densitometry is the result of three individual experiments where intensity of the p611-CTF bands were 
compared to the intensity of 611-CTF bands on the same gel (*p<0.05). 
 
We also observed increased phosphorylation of cortactin, a known downstream target of 
611-CTF (Figure 3-4, p=0.039)[222].  611-CTF has been described as a 110 kDa alternative 
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translation product of HER2 containing the c-terminal, intracellular and transmembrane domains 
along with a truncated extracellular domain[223].  611-CTF has been shown to promote tumor 
growth and metastasis in breast cancer cells in vivo[224] and it has also been implicated in cell 
motility and invasiveness[222], further enforcing its metastatic function.   
 
Figure 3-4. Increased phosphorylation of cortactin, a downstream effector of activated 611-CTF, in 
cetuximab resistant cells. 
Cell lysates were collected under basal conditions when cells reached 70% confluence.  Whole lysates were 
analyzed by Western Blot and probed for pSerine and cortactin.  Densitometry is the result of six individual 
experiments where intensity of the pSerine bands for each cell type was compared to their respective cortactin bands 
from the same gel.  Phosphorylation ratios for each cell line were compared to the T24 cell line for reference 
(*p<0.05). 
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3.3.4 Inhibiting HER2 Can Restore Sensitivity to Cetuximab In Vitro 
To determine the functional role of phosphorylated 611-CTF in mitigating resistance to 
cetuximab, we treated T24PR3 cells with cetuximab and HER2 shRNA or various HER2-
targeting agents.  First, we used lentiviral shRNA transduction to knock down full-length HER2 
and 611-CTF in four separate clones of T24PR3 (Figure 3-5A).  HER2 knockdown in clones 2 
and 4 reduced full-length HER2 by 70% and 78%, respectively, compared to non-targeting 
scrambled shRNA-transduced control cells.  Likewise, HER2 knockdown in clones 2 and 4 
reduced 611-CTF expression by 46% and 56%, respectively, compared to scrambled shRNA-
transduced cells.  This HER2 knockdown of full-length HER2 and 611-CTF was able to restore 
the effect of cetuximab on T24PR3 cells in culture.  Cetuximab decreased invasion of the HER2 
shRNA-transduced cells by 54.9% (p=0.047) and 49.5% (p=0.034) after 24 hours.   
To determine if the effects of HER2 knockdown were due to knockdown of the full-
length HER2 or the 611-CTF fragment, we used HER2-targeting agents to selectively and 
functionally inhibit HER2 activity.  Trastuzumab is a monoclonal antibody targeting exclusively 
full-length HER2 and should not interact directly with 611-CTF which lacks the extracellular 
region containing the trastuzumab epitope[225].  Although trastuzumab alone only decreased 
invasion of T24PR3 cells by 14.5%, the combination of cetuximab plus trastuzumab decreased 
invasion by 43.8% (Figure 3-5B, p=0.01).  While there are currently no kinase inhibitors 
available for use in the clinic that target HER2 selectively, afatinib is an irreversible kinase 
inhibitor targeting both EGFR and HER2.  Afatinib is currently in phase II trials for prostate 
cancer, glioma, and head and neck cancer as well as phase III clinical trials for breast cancer and 
non-small cell lung carcinoma[226]. We found that afatinib alone could inhibit the invasion of 
 90 
T24PR3 cells by 38.1% (Figure 3-5C, p=0.03), and the combination of cetuximab plus afatinib 
inhibited the invasion of T24PR3 cells by 62.1% (Figure 3-5C, p=0.031).   
 
 
Figure 3-5. Inhibition of HER2 restores cetuximab sensitivity in vitro. 
(A) T24PR3 cells were transduced with HER2 shRNA-containing lentiviral particles and a representative image of 
the western blots for full length HER2 and 611-CTF from 4 clones and scramble control lysates are included here.  
Invasion studies in this figure were performed using 1µM cetuximab or drug free media (*p<0.05) and all data are 
the result of two independent experiments run in duplicate.  (B) Invasion studies were performed using T24PR3 
cells with media containing either vehicle, cetuximab, trastuzumab to inhibit full length HER2, or both cetuximab 
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and trastuzumab. (C) Invasion studies were performed using T24PR3 cells with media containing either vehicle, 
cetuximab, the EGFR-HER2 kinase inhibitor afatinib, or both cetuximab and afatinib.   
While we did not directly examine interactions between cetuximab and selective EGFR 
kinase inhibitors in an invasion assay, we performed drug response assays with an EGFR kinase 
inhibitor using cell metabolism as a readout in both cetuximab resistant and cetuximab sensitive 
cells.  The cetuximab resistant and cetuximab sensitive cells demonstrated similar IC50s to the 
EGFR kinase inhibitor erlotinib, 6.37µM and 9.99µM, respectively (p=n.s.).  In contrast, the IC50 
of cetuximab-resistant cells treated with afatinib was 8.27nM (Figure 3-6).  These data suggest 
that co-targeting EGFR with a dual-specificity tyrosine kinase inhibitor that can also inhibit 
HER2 and 611-CTF may enhance the effects of EGFR targeting in vitro in a cetuximab-resistant 
cell model. 
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Figure 3-6. Cetuximab resistant cells are more sensitive to afatinib than erlotinib. 
Cells were plated to be 50% confluent and treated with varying doses of either afatinib, erlotinib, or DMSO control.  
After 72 hours, an MTT assay was performed.  Data is the result of three independent experiments run in triplicate. 
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3.3.5 Dual Kinase Inhibition of EGFR and HER2 Can Enhance the Anti-Tumor Effects 
of Cetuximab In Vivo 
In order to test the effects of EGFR and HER2 kinase inhibition on mediating cetuximab 
sensitivity in vivo, we generated xenografts in athymic nude mice by inoculating cetuximab 
sensitive cells on one flank and cetuximab resistant cells on the other flank of the same mouse 
(n=40 mice).  Following tumor formation, animals were randomized based on tumor volumes 
and treated with vehicle control, cetuximab alone, afatinib alone, or cetuximab plus afatinib.  
After 21 days, the treatment regimen of cetuximab plus afatinib yielded a 76.5% reduction in 
cetuximab-resistant tumor volumes (p=0.0191) compared to vehicle control treated tumors 
(Figure 3-7A).   
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Figure 3-7. Anti-tumor effects of dual kinase inhibition of EGFR and HER2 in vivo. 
Xenografts were created using cetuximab-resistant T24PR3 cells (A) or cetuximab-sensitive T24 cells (B) in 
athymic nude mice (n= 40).  Mice were randomized based on tumor volumes and treated with vehicle control, 
afatinib (0.4mg/daily by oral gavage), cetuximab (1.0mg 3x/week by i.p. injection), or both drugs concurrently for 
21 days. Tumor volumes were measured 3 times per week for a total of 3 weeks.  P-values were generated using a 
Mann-Whitney Test (*p<0.05).  
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A similar reduction in tumor volumes was seen in cetuximab-sensitive tumors treated 
with cetuximab and afatinib (89.7%, p=0.0191) (Figure 3-7B), although no additional benefit 
was observed from adding afatinib to cetuximab therapy in cetuximab-sensitive xenografts 
because of the already potent anti-tumor effects of cetuximab on these tumors. The difference in 
tumor volumes between the cetuximab-sensitive and cetuximab-resistant xenografts treated with 
cetuximab was again significant (p=0.0013) as shown earlier with a higher dose of cetuximab 
(Figure 2-2A). 
 Interestingly, 611-CTF expression in the cetuximab-resistant tumors was significantly 
increased in tumors treated with cetuximab alone but decreased in those treated with the 
combination of afatinib and cetuximab (Figure 3-8, p=0.015 and p=0.0047, respectively).  611-
CTF expression was slightly increased in the afatinib treated tumors, although this difference 
was not statistically significant (Figure 3-8, p=0.11).  Further, the dramatic reduction in 
cetuximab-resistant tumor volumes that was seen with the combination of cetuximab plus 
afatinib far surpasses the effect observed when either agent was used as a monotherapy, which 
suggests that dual kinase inhibition of EGFR and HER2 may be an effective way to enhance the 
efficacy of cetuximab in vivo in the context of acquired resistance. 
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Figure 3-8. 611-CTF is lost in tumors treated with cetuximab and afatinib. 
Cell lysates were created from snap-frozen tumor tissue.  Whole lysates were analyzed by Western Blot and probed 
for 611-CTF.  Densitometry is the result of four technical replicates from one individual tumor of each treatment 
group normalized to the β-tubulin loading control for each tumor (*p<0.05, **p<0.005). 
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3.4 DISCUSSION 
HER kinase receptor switching has been described as a major determinant of acquired 
resistance to inhibition of these receptors[155].  For this reason, we decided to examine the 
expression and activation of other ErbB family members in our cetuximab-resistant models.  
While we observed no marked differences in ErbB family expression or activation across the five 
cell lines tested in vivo, the HER2 fragment 611-CTF was most robustly expressed in the T24 
cell line and the SCC1 cell line, which was used to generate the previously published in vitro 
model of cetuximab resistance. Our results associate 611-CTF with cetuximab resistance and 
suggest that therapeutic targeting of both HER2 and 611-CTF in combination with cetuximab is 
highly efficacious in vitro and in vivo (Figure 3-5, Figure 3-7).   
The exact mechanism of the increased anti-tumor activity seen with the addition of 
afatinib to cetuximab and to what extent inhibiting 611-CTF plays a role in this mechanism 
remains incompletely understood. Interestingly, 611-CTF is thought to be hyperactive because of 
its ability in models of forced expression to constitutively homodimerize through disulfide bonds 
as a result of unbalanced extracellular cysteine residues[224].  It is unclear from the literature 
whether 611-CTF can heterodimerize with full length HER2 or the other ErbB family members.  
The endogenous presence of non-phosphorylated 611-CTF in several cell lines including A431, 
SCC1, SCC1c8, and T24 cells (Figure 3-3) suggests that 611-CTF is not always a constitutively 
active receptor fragment and that it may require heterodimer partners for activation under some 
conditions.  ErbB receptor heterodimerization might also explain, in part, the anti-tumor activity 
of the trastuzumab/cetuximab combination in the cetuximab and trastuzumab-resistant T24PR3 
model. One limitation of the present study is that the precise mechanism of resistance and 611-
CTF activation could not be elucidated due to the low levels of endogenous 611-CTF expression 
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in our cell lines and our attempts at cloning constitutively active and kinase dead forms of 611-
CTF for forced expression studies have been unsuccessful to date.   
Combinatorial treatment regimens are currently at the forefront of growth factor 
molecular targeting[155, 227].  Two recent preclinical reports describe the in vivo benefit of 
combining cetuximab with kinase inhibitors specific for EGFR and/or HER2, although in both 
cases the work was performed in the context of an acquired mutation (T790M) that confers 
resistance to the EGFR tyrosine kinase inhibitor gefitinib[134, 228].  Both these studies and the 
current one provide complementary data supporting the use of a treatment regimen that is 
particularly timely and pertinent with ongoing phase I clinical trials in solid tumors of afatinib 
plus cetuximab (ClinicalTrials.gov Identifier: NCT01090011) or lapatinib plus cetuximab 
(ClinicalTrials.gov Identifier: NCT01184482).  Surprisingly, there is very little data describing 
molecular mechanisms in support of this treatment regimen.   
One recent report shows that the combination of cetuximab with lapatinib can increase 
antibody-dependent cell mediated cytotoxicity (ADCC) in 51Cr-release assays by up to 
30%[229].  The mechanism by which ADCC is increased with this treatment modality remains 
unknown, as the authors of the same study do not show a high frequency of lapatinib-mediated 
accumulation of EGFR at the cell surface as is seen for HER2 with lapatinib and trastuzumab 
combination treatments[230].  Both studies demonstrate lapatinib-mediated accumulation of 
inactive HER2 at the cell surface due to loss of ubiquitination and degradation[229, 230], which 
may explain in part our observation that afatinib does not decrease the expression of 611-CTF in 
xenografts (Figure 3-8) despite decreasing tumor volume.  These data are concordant with 
published work[230] that shows lapatinib can decrease tumor volumes in animals despite 
increased accumulation of HER2.   
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Collectively, these data indicate that kinase inhibition of HER2 and EGFR may enhance 
sensitivity to cetuximab.  To what extent inhibiting 611-CTF may play a role in this enhanced 
sensitivity remains unknown.  Further, the contribution that activated expression of 611-CTF 
may make to cetuximab resistance is also elusive.  The data presented here associate 611-CTF 
with cetuximab for the first time, and provide a potential mechanism for the enhanced response 
seen when cetuximab is combined with a kinase inhibitor of EGFR and HER2. 
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4.0  C-MET AND EGFR KINASE INHIBITORS ARE SYNERGISTIC THROUGH 
DEACTIVATION OF THE MAPK PATHWAY 
4.1 INTRODUCTION 
As is the case with cetuximab resistance, no singular mechanism of resistance to EGFR 
kinase inhibitors has been established apart from c-Met amplification or genetic alterations 
(Paragraph 1.3.3).  Importantly, neither c-Met amplification nor these other well-known genetic 
alterations (EGFR gatekeeper mutation, K-Ras activating mutations) can account for the entirety 
of EGFR TKI resistance.  The extent to which c-Met may contribute to EGFR kinase inhibitor 
resistance in HNSCC has not been well described, but is precedent in other cancer types 
including lung cancer.  In contrast to mAb resistance, HER2 and HER3 signaling has been 
implicated in EGFR inhibitor sensitivity, not resistance.  This association has not been examined 
in HNSCC, making these receptors valid additional targets to examine in the context of EGFR 
inhibitor sensitivity. 
4.1.1 c-Met Signaling in Erlotinib Response 
Activation of other receptor tyrosine kinases may confer growth and survival in the 
presence of EGFR blockade. Signaling through receptor tyrosine kinases is highly redundant: co-
activation of multiple receptors has been shown to limit the efficacy of individual targeting[155].   
The hepatocyte growth factor receptor, c-Met, is a receptor tyrosine kinase that signals 
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downstream through many of the same pathways as EGFR.  c-Met is correlated with poor 
prognosis in HNSCC[231], and has been proposed as a molecular co-target with EGFR in 
HNSCC[158].  c-Met has been shown to play a compensatory role for EGFR kinase activity in 
breast cancer[232], and is found to be amplified in TKI-resistant lung cancer tumors[157]. We 
recently reported that HGF and c-Met participate in a paracrine growth pathway in HNSCC[233] 
and new data demonstrate that combined targeting of EGFR and c-Met leads to synergistic 
growth inhibition in HNSCC cells[234].  
4.1.2 HER2 and HER3 Signaling in Erlotinib Response 
Although it is counterintuitive, several preclinical models describe increased HER2 and 
HER3 expression as a mechanism of sensitizing cells to EGFR inhibitors.  Inhibition of HER2 by 
erlotinib has been reported to occur by direct binding of erlotinib to HER2 in the absence of 
EGFR[235].  EGFR kinase inhibition can also reduce phosphorylation of HER2 or HER2/HER3 
heterodimers in cell systems when EGFR levels are low[236].  Increased HER3 RNA levels are 
associated with EGFR TKI sensitivity in HNSCC cell lines[237] and breast cancer cells 
overexpressing HER2 have been shown to have heightened sensitivity to EGFR TKI in vitro  and 
in vivo[238].  Erlotinib-mediated reductions in HER2/HER3 signaling decrease cell survival by 
blocking AKT association with HER3 that is normally required for AKT phosphorylation[239].   
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4.2 MATERIALS AND METHODS 
4.2.1 Cells and Reagents 
HN-5, OSC-19, UM-22A, SCC1 and CAL33 are primary HNSCC cell lines and UM-
22B, PCI-15B, and 686LN are derived from metastatic cervical lymph nodes from patients with 
HNSCC[176].  OSC-19 cells were maintained in MEM with 10% FBS and 1% non-essential 
amino acids.  SCC1 was maintained in DMEM with 10% FBS and 0.4ug/mL hydrocortisone.  
HN-5 and 686LN cells were maintained in DMEM/F-12 + 10% FBS.  PCI-15B, UM-22A, UM-
22B, and CAL33 cells were maintained in DMEM + 10% FBS.  ).  HeLa cells are a cervical 
cancer cell line maintained in DMEM + 10% FBS[179].  UM-22A and UM-22B cells were a 
generous gift from Dr. Tom Carey (University of Michigan), PCI-15B cells were a generous gift 
from Dr. Theresa Whiteside (University of Pittsburgh) and SCC1 cells were a generous gift from 
Dr. Paul Harari (University of Wisconsin). All cell lines were validated by genotyping within 6 
months of their use using the AmpFISTR Identifiler System (Applied Biosystems).  Erlotinib 
was purchased from Chemietek and resuspended in DMSO for cell studies and SU-11274 was 
purchased from Calbiochem and also resuspended in DMSO for cell studies. 
4.2.2 Immunoprecipitations 
Immunoprecipitations were performed on whole cell lysates collected 48h after plating 
using protein G-linked agarose beads with anti-PY99 (Santa Cruz).  Immune serum and the 
remaining supernatant was resolved on SDS-PAGE gels and immunoblotted (Flk-2, Santa Cruz; 
IGF-1RB, Santa Cruz; c-Met, Santa Cruz).  
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4.2.3 Immunoblotting and Statistical Analyses 
Immunoblots shown here were performed on whole cell lysates collected when cells were 
approximately 70% confluent.  Basal conditions were used for all lysates except 686LN and 
HeLa cells which were serum starved for 2 hours in the presence of 1µM erlotinib or 1µM SU-
11274, a c-Met kinase inhibitor. Following 2 hour serum starvation, 686LN and HeLa cells were 
stimulated with EGF (10ng/mL) or HGF (40ng/mL) for 5 minutes and lysates were collected. 
All lysates were resolved on SDS-PAGE gels and immunoblotted with either α-HER2 
and α-pHER2 (Y1248, Cell Signaling), α-HER3 (Santa Cruz Biotechnologies), α-AKT and α-
pAKT (S473, Cell Signaling), α-p24/44 (MAPK, Cell Signaling) and α-phospho-p42/44 
(pMAPK, Cell Signaling), or  α-Met (Cell Signaling) and α-pMet (Y1234/5, Cell Signaling) 
antibodies.  Nonparametric Spearman correlations were used to determine the relationship of c-
Met protein levels and c-Met phosphorylation levels as well as HER3 protein levels to erlotinib 
IC50. 
4.2.4 Combination Index Analysis 
30,000 cells were plated in triplicate wells of three 24-well plates.  The following day, 
each plate was treated with erlotinib, SU-11274, or both drugs in combination across a range of 
doses from 5 to 20 µM along with vehicle controls.  After 72 hours, an MTT assay was 
performed.  Combination index (CI) was generated using titrated dosing at a fixed ratio of SU-
11274:erlotinib (1:1.69) based on the IC50 of each drug separately.  CI =(Da + Db) / (Dxa + Dxb) 
+ DaDb / DxaDxb; where Da and Db are the doses of drug A and B that stimulate X% of cell 
viability as single drugs, and Dxa and Dxb are doses of drug A and B that stimulate X% of cell 
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viability in a combination regimen.  Combination index values were calculated using CalcuSyn 
Software (BioSoft).   
4.2.5 siRNA Experiments  
30,000 cells were plated in duplicate in a 24-well plate.  Cells were transfected with 
100nM c-Met pooled siRNA (Dharmacon) or scrambled siRNA (Dharmacon) for 4 hours with 
Lipofectamine (Invitrogen) in OptiMem media (Gibco).  After 24 hours, vehicle control or twice 
the IC50 dose of erlotinib was added to the cells in 24-well plates for another 24 hours at which 
point cell metabolism assays were performed.  Whole cell lysates were harvested simultaneously 
to confirm c-Met knockdown from cells transfected in parallel. 
4.2.6 c-Met Transfection 
30,000 cells were plated in duplicate in a 24-well plate.  Cells were transfected with 
either 2ug human c-Met cloned into a pcDNA3.1(+) expression vector (courtesy of Dr. Reza 
Zarnegar at the University of Pittsburgh) or pcDNA3.1(+) empty vector construct for 4 hours 
with Lipofectamine (Invitrogen) in OptiMem media (Gibco).  After 24 hours, vehicle control or 
twice the IC50 dose of erlotinib was added to the cells in 24-well plates for another 24 hours, at 
which point MTT assays were performed.  Whole cell lysates were harvested simultaneously to 
confirm c-Met expression from cells transfected in parallel.   
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4.3 RESULTS 
4.3.1 Basal Activation of HER2 and HER3 Signaling Is Not Associated with Erlotinib 
Response 
In order to test whether HER2 and HER3 signaling may confer sensitivity to kinase 
inhibition in HNSCC cells, we screened a panel of HNSCC cells with varying response to the 
EGFR kinase inhibitor erlotinib (Paragraph 2.3.4) for HER2 protein phosphorylation.  Whole 
cell lysates collected under basal conditions did not demonstrate a correlation between erlotinib 
sensitivity and HER2 protein expression or phosphorylation (Figure 4-1). 
 
Figure 4-1. HER2 phosphorylation does not correlate with erlotinib sensitivity. 
Cell lysates were collected under basal conditions when cells reached 70% confluence.  Whole lysates were 
analyzed by Western Blot and probed for HER2 and pHER2 (Cell Signaling).  
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In agreement with the lack of correlation between HER2 expression and phosphorylation 
with erlotinib response, HER3 protein expression did not correlate with response to erlotinib 
sensitivity (Figure 4-2).   
 
Figure 4-2. HER3 protein expression does not correlate with erlotinib sensitivity. 
A. Representative Western Blot where cells were 70% confluent when lysates were collected.  Proteins were 
resolved on an 8% SDS-PAGE Gel and transferred to nitrocellulose membrane that was blotted with α-HER3 (Santa 
Cruz Biotechnologies).  B.  HER3 expression does not correlate with response to erlotinib (r=0.5952, p=0.1323).  
Densitometry was calculated using Image J and statistical correlations were calculated using a non-parametric, two-
tailed Spearman correlation in GraphPad Software. Data is the result of two independent experiments. 
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Due to technical issues with the limited phospho-specific HER3 antibodies currently 
available, we were unable to gain a reproducible immunoblot of HER3 phosphorylation in these 
lysates.  Because HER2-mediated EGFR TKI sensitivity works through HER3 
heterodimerization and AKT activation[239], we examined AKT activation in this panel of 
HNSCC cells to serve as a surrogate marker of HER3 activity.  AKT phosphorylation at S473 is 
a marker of AKT activity because this is one of two residues for which phosphorylation is 
required to permit activation of the kinase[240].  We did not observe any remarkable changes in 
AKT expression or phosphorylation across the panel of HNSCC cells (Figure 4-3), suggesting 
that HER2/HER3-mediated activation of AKT under basal conditions may not play a large role 
in determining erlotinib response in HNSCC cells. 
 
Figure 4-3. AKT phosphorylation does not correlate with erlotinib response. 
Cell lysates were collected under basal conditions when cells reached 70% confluence.  Whole lysates were 
analyzed by Western Blot and probed for AKT and pAKT (Cell Signaling). 
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4.3.2 c-Met is Hyperphosphorylated in an Erlotinib Resistant Cell Line 
Because EGFR downregulation correlates with decreased sensitivity to EGFR inhibitors 
(Figure 2-8) but no association was observed between HER2/HER3 signaling and erlotinib 
sensitivity, we examined other growth factor receptors that may function independently of EGFR 
to activate the same downstream effectors in the context of erlotinib resistance. IGF-1Rβ has 
been proposed as a heterodimerization partner with EGFR in HNSCC[241], and drugs targeting 
VEGFR2 (flk-1) have demonstrated dose-dependent inhibition of EGFR which suggests a role 
for VEGF in EGFR signaling[242].  Immunoprecipitations with α-phosphotyrosine were 
performed on TKI-sensitive 686LN cell lysates and Flk-1, IGF-1Rβ, and c-Met were detected by 
western blot. HeLa cell lysates were used as an erlotinib-resistant control.  A dramatic reduction 
in c-Met phosphorylation was seen in the 686LN cells compared with the TKI-resistant HeLa 
cells (Figure 4-4) and this was confirmed by immunoblotting on whole cell lysates (data not 
shown). 
                  
Figure 4-4. c-Met is hyperphosphorylated in an erlotinib resistant cell line. 
Immunoprecipitations were performed using α-PY99 (Santa Cruz) and whole cell lysates with protein G-linked 
agarose beads, resolved on SDS-PAGE gels and immunoblotted (α -Flk-1, α-IGF-1Rβ, α-c-Met, Santa Cruz).   
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 --      +       --        --     +     -- 
 --      --       +        --    --      + 
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4.3.3 c-Met Inhibition is Synergistic with EGFR Kinase Inhibition 
To determine the therapeutic significance of decreased c-Met activity in erlotinib 
sensitive cells, I examined the effects of co-targeting c-Met and EGFR in TKI-resistant cells.  
Combination studies were performed in vitro using erlotinib and SU-11274 (Calbiochem), a c-
Met TKI.  SU-11274 is known to be synergistic with erlotinib in HNSCC cells[158, 234], and 
here we report synergistic inhibition of cellular metabolism in the TKI-resistant HeLa cells using 
SU-11274 and erlotinib. Based on inhibition of cellular metabolism in the presence of erlotinib, 
SU-11274 or both drugs concurrently, a combination index  (CI) value can be determined using 
the formula of Chou and Talalay[243] (Paragraph 4.2.4).   Using this model, a CI>1 is 
representative of an antagonistic response, a CI=1 is representative of an additive response, and a 
CI<1 is representative of a synergistic response. The average CI=0.774±0.05 for HeLa cells 
treated concurrently with erlotinib and SU-11274, indicating a synergistic response when these 
two drugs are combined in vitro (Figure 4-5).  The synergistic benefit of co-targeting EGFR and 
c-Met in vitro suggests that further exploring the role of c-Met in TKI resistance  may help 
identify signaling molecules downstream of EGFR and c-Met that could serve as molecular co-
targets with EGFR inhibitors.  
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Figure 4-5. c-Met inhibition is synergistic with EGFR inhibition. 
Decreases in HeLa cell metabolic activity determined by 72h MTT assay when erlotinib is combined with the c-Met 
inhibitor SU-11274 at a ratio of 1.69:1, respectively, with [SU-11274] in 1µM intervals from 5-11. The combination 
index value=0.774±0.05 describes synergy between erlotinib and SU-11274.  (>1=antagonistic response, 1=additive 
response, <1=synergistic response). 
 
Because we did not observe changes in AKT activity in cell lines with varying responses 
to erlotinib, we hypothesized that the synergistic effects of erlotinib and SU-11274 may stem 
from deactivation of the MAPK pathway.  In accordance with the synergistic effect that is 
observed in cell metabolism assays when erlotinib is combined with SU-11274, we observed a 
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marked reduction of MAPK activity when TKI-resistant HeLa cells were treated with erlotinib 
and SU-11274 prior to stimulation with EGF and HGF (Figure 4-6).  We also tested this 
deactivation of MAPK in TKI-sensitive 686LN cells, and found the same result: inhibition of c-
Met and EGFR is required for deactivation of MAPK in the presence of EGFR and c-Met 
stimulatory ligands (Figure 4-6).  This result demonstrates that when EGFR and c-Met signaling 
is blocked simultaneously, regardless of response to EGFR kinase inhibition, MAPK is 
deactivated.  Further, when either EGFR or c-Met is inhibited singularly, signaling to MAPK 
through the other receptor can compensate for this blockade. 
 
 
Figure 4-6. Inhibition of c-Met and EGFR is required for decreased MAPK activation. 
686LN and HeLa cells were plated at 70% confluency.  The following day, cells were serum starved for 2 hours in 
the presence of either 1µM erlotinib or 1µm SU-11274 as indicated.  Cells were then stimulated with either EGF 
(10ng/mL) or HGF (40ng/mL) for 5 minutes.  Cell lysates were harvested on ice and resolved on an SDS-PAGE gel 
and transferred to a nitrocellulose membrane.  Membranes were probed for p24/44 (MAPK, Cell Signaling) or 
phospho-p42/44 (pMAPK, Cell Signaling). 
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4.3.4 c-Met is Not Amplified in an HNSCC Patient Cohort 
c-Met amplification has been reported in lung cancer primarily as a major mechanism of 
acquired resistance to EGFR kinase inhibition[151], although de novo c-Met amplification is 
observed at a rate of 2-3% in some EGFR kinase inhibitor naïve patients[218].  We hypothesized 
that c-Met amplification may provide a compensatory mechanism of MAPK activation in the 
context of erlotinib resistant HNSCC.  Only one group has examined c-Met amplification status 
in HNSCC, reporting 15/23 (65%) tumors with amplified c-Met independent of EGFR TKI 
treatment as determined by quantitative polymerase chain reaction (qPCR)[158].  To examine a 
larger cohort of patients, we performed FISH on 77 primary HNSCC tumors and 16 recurrent 
HNSCC tumors.  Our cohort was comprised of 73.1% males and had a median age of 61.  Oral 
cavity and oropharynx tumors comprised 64.5% of our tumor samples and the majority of tumors 
were stage IV (50.5%).  Complete demographics of this cohort can be found in Table 4-2.  The 
FISH analysis conducted by Drs. Simion Chiosea and Sanja Dacic at the University of Pittsburgh 
Medical Center revealed  0/77 and 0/16 c-Met amplifications in primary and recurrent HNSCC 
tumors, respectively (Table 4-1).  Drs. Chiosea and Dacic also tested 8 of our HNSCC cell lines 
for c-Met amplification to determine if they were representative of our patient population and we 
found that c-Met was amplified in 0/8 cell lines, concordant with our patient samples (Table 
4-1).   All c-Met:CEP7 ratios in both tumors and cell lines were below 2.0, which is the threshold 
for determining amplification.  While our cohort size lacks the statistical power to achieve 
significance for an amplification that occurs at a rate of 2% in lung cancer, these data suggest 
that de novo c-Met amplification may not occur in HNSCC.  
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Cell Lines 
Total 
Cells 
Analyzed 
FISH 
Ratio 
Percent 
High 
Polysomy 
Percent Low 
Polysomy 
Percent 
Trisomy 
Percent 
Disomy 
UM-SCC-22A 60 0.72 1 (1.7%) 4 (6.7%) 32 (53.3%) 23 (38.3%) 
UM-SCC-22B 60 0.83 2 (3.3%) 5 (8.3%) 34 (56.7%) 19 (31.7%) 
686LN 62 0.71 17 (27.4%) 21 (33.9%) 15 (24.2%) 8 (12.9%) 
LICR-LON-HN5 61 0.66 6 (9.8%) 37 (60.7%) 17 (27.9%) 1 (1.6%) 
0SC-19 60 0.72 0% 24 (40%) 9 (15%) 27 (45%) 
UM-SCC-1 63 0.83 5 (7.9%) 43 (68.3%) 13 (20.6%) 2 (3.1%) 
PCI-15B 60 1.14 50 (83.3%) 3 (5%) 7 (11.7%) 0% 
CAL33 62 1.02 0% 51 (85.0%) 6 (9.7%) 5 (8.1%) 
       
Tissue 
Total 
Samples 
Analyzed 
Average 
FISH 
Ratio 
Average 
Percent 
High 
Polysomy 
Average 
Percent Low 
Polysomy 
Average 
Percent 
Trisomy 
Average 
Percent 
Disomy 
Primary HNSCC 77 1.05 0.8% 4.2% 15.7% 82.4% 
Recurrent HNSCC 16 1.15 0% 5.6% 10.4% 83.7% 
       
Table 4-1. c-MET copy number in HNSCC tumors and cell lines 
FISH was performed on 77 primary and 16 recurrent HNSCC tumors as well as 8 HNSCC cell lines.  FISH Ratio of 
CEP7:c-Met staining was analyzed for each specimen.  Each cell analyzed was assigned to a category of High 
Polysomy, Low Polysomy, Trisomy or Disomy based on FISH ratio and averages for each cell line and tumor type 
are given here.  FISH was performed and analyzed by Drs. Simion Chiosea and Sanja Dacic. 
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All Cases 
n=93 
Gender     
   Male 68 73.1% 
   Female 25 26.9% 
Age     
   Median (Range) 61 (19-85) 
Tumor Type     
   Primary 77 82.8% 
   Recurrence 16 17.2% 
Tumor Site     
   Oral Cavity 40 43.0% 
   Oropharynx 20 21.5% 
   Hypopharynx 1 1.1% 
   Nasopharynx 1 1.1% 
   Larynx 23 24.7% 
   Neck 5 5.4% 
   Sinus 3 3.2% 
Disease Stage     
   0-1 17 18.3% 
   II 5 5.4% 
   III 14 15.1% 
   IV 47 50.5% 
   Recur/Met Unstaged 10 10.8% 
Table 4-2. Demographics of c-Met FISH HNSCC patient cohort.    
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4.3.5 c-Met Phosphorylation is Not Correlated with Erlotinib Response 
In the absence of any frequent c-Met amplification, we sought to determine if basal c-Met 
activation may correlate with response to erlotinib in HNSCC cells.  One group has reported that 
c-Met protein expression is not associated with response to erlotinib in HNSCC clinical 
trials[244], although they did not examine the relationship between c-Met phosphorylation and 
erlotinib response.  We used phosphorylation at Tyr1234/5 as a surrogate marker of c-Met 
activation since this is the residue at which phosphorylation leads to downstream MAPK 
activation[245].  All cell lines demonstrated protein expression of the c-Met receptor, and we 
observed a broad spectrum of basal c-Met phosphorylation across the cell lines (Figure 4-7).  
Densitometry from three independent western blots was used to determine c-Met expression 
normalized to β-tubulin and c-Met phosphorylation normalized to total c-Met protein expression.  
A non-parametric Spearman correlation was used to examine the relationship between erlotinib 
response and c-Met protein levels and phosphorylation levels.  In both cases, c-Met protein 
expression and c-Met protein phosphorylation, there were no significant associations with 
erlotinib response (p=0.9349 and p=0.8401, respectively).  The fact that c-Met activity is not 
inversely correlated with erlotinib sensitivity suggests that while concurrent EGFR and c-Met 
inhibition is synergistic, c-Met activity may not be required for erlotinib resistance. 
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Figure 4-7. Neither c-Met activation nor expression correlates with erlotinib response. 
A representative Western Blot is shown where cells were grown to 70% confluency and lysates were collected.  
Proteins were resolved on an 8% SDS-PAGE Gel and transferred to nitrocellulose membrane that was blotted with 
α-Met (Cell Signaling) or α-pMet (Cell Signaling).  Densitometry was calculated using Image J from three 
independent experiments and statistical correlations were calculated using GraphPad Software.  Met expression and 
phosphorylation do not correlate with erlotinib response ( p=0.9349 and p=0.08401, respectively). 
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4.3.6 Altering c-Met Protein Levels Does Not Affect Response to Erlotinib 
To determine whether activation of c-Met confers resistance to erlotinib, we used siRNA 
to genetically knock down c-Met expression in erlotinib resistant cell lines and examined the 
response of the cells to erlotinib.  c-Met was knocked down in HeLa cells and response to 
erlotinib was determined by cell metabolism assays 48 hours following erlotinib treatment at a 
range of doses from 500nM  to 50µM.  Genetic suppression of c-Met expression did not alter the 
IC50 of HeLa cells treated with erlotinib (Figure 4-8A).   
c-Met was also knocked down in UM-22A and CAL33 cell lines and response to erlotinib 
was determined by cell metabolism assay 24 hours following treatment.  Erlotinib decreased cell 
viability by 33.08±0.26% in vector transfected UM-22A cells and by 31.67±1.22% in UM-22A 
cells transiently transfected with c-Met siRNA (p=0.37, Figure 4-8B).  Likewise, erlotinib 
decreased cell viability by 53.00±3.80% in vector transfected CAL33 cells and by 51.39±23.04% 
in CAL33 cells transfected with c-Met siRNA (p=0.95, Figure 4-8B).  These data suggest that 
transient knockdown of c-Met is not capable of enhancing cellular response to erlotinib.  
In line with this, we wanted to determine if c-Met activation is sufficient to confer 
resistance to erlotinib.  We transiently transfected PCI-15B cells with c-Met DNA or vector 
control DNA and determined response to erlotinib by cell metabolism assays 24 hours after the 
start of treatment.  Erlotinib decreased the cell viability of PCI-15B cells by 31.67±23.16% in 
vector control transfected cells and by 33.78±25.10% in c-Met transfected cells (p=0.47, Figure 
4-8C).  These data suggest that c-Met is not sufficient for conferring erlotinib resistance in 
HNSCC cells. 
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Figure 4-8. Altering c-Met protein level does not affect response to erlotinib. 
A. HeLa cells were plated in 96-well plates at a density of 10,000 cells per well.  After 24 hours, cells were left 
untransfected or transfected with 100nM c-Met or scrambled siRNA.  The following day, cells were treated with 
varying concentrations of erlotinib from 500nM to 50µM or DMSO control.  Cell metabolism assays (MTT) were 
performed after 48 hours of drug treatment.  Whole cell lysates were harvested on cells transfected in parallel to 
confirm c-Met knockdown.  Data is the result of one experiment.  B. UM-22A  or CAL33 cells were plated in 24-
well plates at a density of 30,000 cells per well.  After 24 hours, cells were transfected with 100nM c-Met or 
scrambled siRNA.  The following day, DMSO control or twice the IC50 dose of erlotinib was added for another 24 
hours at which point cell metabolism assays (MTT) were performed.  Whole cell lysates were harvested on cells 
transfected in parallel to confirm c-Met knockdown.  Data is the result of two independent experiments run in 
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duplicate.  C. PCI-15B cells were plated in 24-well plates at a density of 30,000 cells per well.  After 24 hours, cells 
were transfected with 2ug c-Met or empty vector.  The following day, DMSO control or twice the IC50 dose of 
erlotinib was added for another 24 hours at which point cell metabolism assays (MTT) were performed.  Whole cell 
lysates were harvested on cells transfected in parallel to confirm c-Met expression.  Data is the result of two 
independent experiments run in duplicate. 
4.4 DISCUSSION 
EGFR tyrosine kinase inhibitors have been studied extensively in both lung cancer and 
HNSCC.  Despite the fact that limited response rates are seen with EGFR TKI use, there is no 
overall survival benefit to erlotinib use in phase III clinical trials in lung cancer[246] and phase 
III data has not been reported in HNSCC.  The greatest benefit in progression-free survival 
during EGFR TKI use occurs in EGFR mutant lung cancer.   The Journal of Clinical Oncology 
recently issued a provisional clinical opinion that EGFR mutation screening should be used as a 
companion diagnostic to determine erlotinib administration in NSCLC[247].  Unfortunately, 
EGFR activating mutations are not found in HNSCC which leaves uncertainty regarding the 
future of erlotinib as a front-line therapy in HNSCC[120].  The studies performed here sought to 
identify novel molecules that may contribute to erlotinib resistance and, as such, could serve as 
co-targets to enhance the efficacy of EGFR TKIs in HNSCC. 
It is reported in the literature that active HER2 and HER3 signaling can sensitize cells to 
EGFR inhibitors when EGFR levels are low due to the ability of erlotinib to bind directly to and 
inhibit HER2[235, 236].  This is in stark contrast to the compensatory signaling from these 
molecules that is known to contribute to EGFR mAb resistance[98, 216].  Because of the 
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conflicting nature of these reports, we wanted to examine the status of HER2 and HER3 activity 
as it relates to EGFR TKI sensitivity.   
In the present study, we examined basal levels of HER2 and HER3 expression.  We also 
looked at HER2 phosphorylation and AKT phosphorylation since it is a downstream effector 
activated by both HER2 and HER3.  We did not observe any alterations to basal HER2 and 
HER3 signaling in association with erlotinib sensitivity.  This suggests that unlike in cetuximab 
resistance, HER2 and HER3 are not differentially contributing to EGFR-independent cell growth 
in cell lines that are less sensitive to EGFR tyrosine kinase inhibition as compared to cell lines 
that are more responsive to EGFR TKIs.   
HER2 and HER3 signaling is also not preferentially activated in the most erlotinib-
sensitive cells.  These cells have the highest levels of EGFR (Figure 2-8), so we believe selective 
EGFR inhibition, not secondary HER2 inhibition, to be the major determinant of EGFR TKI 
sensitivity in these cells.  Either way, our findings do not indicate a role for HER2 or HER3 
expression or activity as a predictor of EGFR TKI response. 
We also wanted to assess the role of c-Met in EGFR tyrosine kinase inhibitor sensitivity 
since c-Met has been proposed as a potential therapeutic co-target with EGFR in HNSCC[158].  
In our studies, we found that de novo c-Met amplification likely does not occur in HNSCC as it 
does in NSCLC (Table 4-1).  Further, we observed a spectrum of c-Met protein expression and 
phosphorylation that does not correlate with EGFR TKI response (Figure 4-7).  We have also 
shown that increasing or decreasing c-Met protein levels is not sufficient to alter cellular 
response to erlotinib (Figure 4-8).  This data suggests that although EGFR is capable of 
activating c-Met through a mechanism of lateral receptor crosstalk[234, 248], this may be a 
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unidirectional mechanism in HNSCC as it does not appear that c-Met is affecting cellular 
response to EGFR inhibition.   
Importantly, despite the lack of cross-talk observed between c-Met and EGFR in these 
models, we did successfully reproduce the published findings that erlotinib and c-Met TKIs have 
synergistic anti-metabolic effects in tumor cells[234].  Further, we have corroborated that this 
mechanism occurs through synergistic reductions in MAPK activity regardless of erlotinib 
response (Figure 4-6).  Our findings suggest that the increased anti-proliferative effects of 
combination treatment observed with EGFR and c-Met inhibition likely stem from the dual 
inhibition of growth signals within the cell that has been previously reported by our group and 
others[158, 234].   
Therefore, we propose that the use of c-Met inhibition for the treatment of HNSCC 
should be considered independently of response to EGFR tyrosine kinase inhibitors.  To date, 
one clinical trial has been published in lung cancer combining a c-Met inhibitor with erlotinib 
and the authors did not report a statistical benefit over treatment with erlotinib plus placebo, 
although a benefit was observed in patients harboring KRAS mutations[249].  KRAS mutations 
are found at a very low frequency in HNSCC, however, suggesting the potentially limited benefit 
to this co-treatment approach in HNSCC[250].   
In summary, we have shown that neither HER2, HER3, nor c-Met signaling correlates 
with response to EGFR tyrosine kinase inhibition.  c-Met alone in not sufficient to alter cellular 
response to erlotinib, but combined targeting of EGFR and c-Met is effective in reducing MAPK 
activity and has synergistic anti-metabolic effects on cancer cells.  While there may be a role for 
 121 
co-targeting of EGFR and c-Met in HNSCC, other treatment modalities that work in conjunction 
with EGFR inhibition to reduce MAPK activity should also be pursued. 
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5.0  GENERAL DISCUSSION 
Squamous cell carcinomas (SCC) are malignant tumors of epithelial origin that comprise 
over 90% of head and neck cancers. HNSCC accounts for approximately 4% of all malignancies 
in the United States[57] and it is the sixth most common cancer worldwide, indicating the large 
public health problem presented by HNSCC[58]. The five year survival rate for oral cancer is 
approximately 50% and first line treatments have historically included chemotherapy and 
radiation as well as surgery[59].  In 2006, cetuximab was FDA approved as the first new 
treatment for head and neck cancer in over 45 years.  Cetuximab was approved at that time for 
the treatment of primary HNSCC in combination with radiation[251] and gained approval in 
2011 for concurrent treatment with platinum-based compounds for recurrent or metastatic 
HNSCC[252].  Despite evidence of limited clinical efficacy with EGFR inhibitors, no one 
biomarker has been established in HNSCC to predict response to these agents. Elucidation of the 
mechanism of resistance to EGFR inhibitors has been limited by: 1) the difficulty in obtaining 
post-treatment tissue from HNSCC patients treated with EGFR inhibitors; and 2) the paucity of 
preclinical models of EGFR inhibitor resistance. 
Two preclinical HNSCC models of resistance to EGFR-targeting agents were recently 
reported. One model is an HNSCC cell clone selected for gefitinib resistance from Dr. Georgia 
Chen at Emory University[161], although this model proved to be HNSCC and HeLa cells upon 
retrospective genotyping.  The other model is an HNSCC cell clone selected for cetuximab 
resistance from Dr. Paul Harari at the University of Wisconsin[162, 163] that has not been 
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reproducible in vivo[164]. Therefore, to determine mechanisms of EGFR inhibitor resistance, 
additional preclinical models are needed.  
5.1.1 Preclinical Models of Cetuximab Resistance in HNSCC 
In this body of work, I have focused extensively on generating reliable models of 
cetuximab resistance in HNSCC because of the ramifications that such models could have on our 
understanding of the molecular basis for resistance to EGFR targeting agents.  I initially 
fashioned my experiments on a report describing the generation of in vivo models of resistance to 
trastuzumab, a monoclonal antibody targeting HER2[180].  This method proved reliable for 
generation of a bladder cancer model of cetuximab resistance.  These bladder cancer models are 
valid models with which to study mechanisms of cetuximab resistance that may be relevant in 
HNSCC, however, as both bladder cancer and HNSCC have widespread EGFR expression and 
lack many of the mutations known to confer resistance to cetuximab in lung and colon cancer. 
I also attempted to generate cetuximab resistant models using HNSCC cell line derived 
xenografts.  I was unable to reproduce the cetuximab model generation in xenografts derived 
from HNSCC cell lines despite manipulating several experimental conditions that are known to 
affect drug response such as dose and tumor volume.  I have had more success in recent 
collaborations with Dr. Sarah Wheeler (University of Pittsburgh) in which we use a heterotopic 
tumorgraft model to serve as a basis for selecting cetuximab resistant tumor cells.  Previous 
studies have shown this model to be more representative of clinical response than cell line 
xenograft studies[187, 188] and we observed cetuximab response rates using these models that 
are more representative of clinical response rates than the widespread sensitivity to cetuximab 
that I have observed in HNSCC cell line derived xenografts.  The preliminary data I have 
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presented here suggests that heterotopic tumorgrafts are a reasonable candidate for future studies 
developing models of cetuximab resistance in HNSCC. 
5.1.2 Co-Targeting HER2 to Enhance Cetuximab Sensitivity 
I used the preclinical model of cetuximab resistance derived from bladder cancer to 
examine the role of HER2, HER3, and c-Met in cetuximab resistance.  With this model, I was 
able to identify increased phosphorylation of an alternative translation product of HER2 in the 
cetuximab resistant cells.  This protein, 611-CTF, is a carboxyl-terminal fragment of HER2.  
611-CTF is targeted with kinase inhibitors and has been implicated in resistance to HER2 
antibodies[253].  My studies showed that cortactin, a downstream mediator of 611-CTF 
signaling[222], is also activated in the context of cetuximab resistance.  
Cortactin is potentially an interesting molecular link between EGFR and HER2 that is 
activated in the context of cetuximab resistance.  There are no published reports describing 
HER2 activation of cortactin apart from what is mediated by 611-CTF.  In contrast, evidence of 
EGF-mediated cortactin expression is widespread and may be mediated by c-Src[254, 255].  
Studies examining 611-CTF signaling to c-Src have not been published.  It is known, however, 
that cortactin can increase invasiveness and chemotaxis towards EGF[256-259] and cortactin has 
been implicated in EGFR endocytosis[260], both of which could be potential mechanisms of 
EGFR-inhibitor resistance.  Further, cortactin has been shown to stabilize the c-Met receptor and 
confer resistance in HNSCC cells to the EGFR kinase inhibitor gefitinib[237, 261].  Cortactin is 
an interesting downstream mediator of ErbB receptor signaling, and my studies suggest that its 
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role in EGFR inhibitor resistance, particularly cetuximab resistance, warrants further 
investigation. 
The studies I have conducted using cetuximab resistant preclinical models demonstrate 
that kinase inhibition of EGFR and HER2 using afatinib can restore sensitivity to cetuximab in 
vitro and in vivo and this occurs in vivo alongside loss of 611-CTF expression.  A clinical trial is 
currently underway where cetuximab and afatinib are being combined for the treatment of 
patients NSCLC.  Early results from this trial are encouraging[J Clin Oncol 29: 2011 (suppl; 
abstr 7525)]; disease control was evident in all patients who received the recommended phase II 
dosing schedule, and confirmed partial responses were observed in 8/22 (36%) of evaluable 
patients.  Owing to these results, this clinical trial has been expanded and these data suggest that 
in vivo modeling of cetuximab resistance may be a valid way to determine novel co-targets for 
the treatment of cancer. 
5.1.3 Preclinical Models of Erlotinib Resistance in HNSCC 
Clinical trials are underway in HNSCC using erlotinib, although it has not gained FDA 
approval for use in the treatment of HNSCC and phase II results do not describe any benefit 
beyond a modest increase in progression-free survival[113].  In the present work, I chose to 
focus on assessing primary as opposed to acquired responses to erlotinib in order to identify a 
biomarker that may serve as a predictor of erlotinib response.  These types of biomarkers for 
primary resistance can facilitate the selection of patients most likely to respond to erlotinib 
treatment during clinical trials as well as provide a rationale for molecular co-targeting with 
erlotinib. 
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Here, I determined the response of several HNSCC cell lines to erlotinib and found that, 
as with cetuximab, EGFR response correlates with EGFR protein expression.  The studies I have 
presented here do not make over-reaching claims of cell line sensitivity versus resistance to 
erlotinib based on in vitro data, but rather include a thorough analysis of erlotinib response 
across multiple HNSCC cell lines, which has not been previously reported.  These data 
demonstrate a range of erlotinib responses in HNSCC cell lines that can be used for correlative 
studies analyzing biomarkers in the preclinical setting. 
 
5.1.4 Co-Targeting of c-Met with Erlotinib 
c-Met has been proposed as a co-target with EGFR kinase inhibition in HNSCC[158, 
234] so I used a panel of HNSCC cell lines with differential responses to erlotinib to examine the 
role of c-Met in erlotinib resistance.  While I was able to reproduce the synergistic effects of 
EGFR and c-Met kinase inhibition regardless of erlotinib response, I did not observe association 
of c-Met activity with erlotinib response.  These results, unfortunately, do not help identify a 
subset of patients in which this co-targeting may be particularly beneficial.  A recent trial 
combining a c-Met kinase inhibitor with erlotinib in NSCLC does not show a benefit above that 
of erlotinib plus placebo[249], and no trials have been published to date combining c-Met 
inhibitors with erlotinib in HNSCC. 
It may be clinically useful to recapitulate the downstream signaling effect of combined 
EGFR and c-Met kinase inhibition on MAPK activity that I and others have observed[234] 
directly by combining erlotinib with a MEK inhibitor.  This approach has not been tested 
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clinically to date, but preclinical data bolsters the rationale for this treatment regimen.  A recent 
study in lung cancer cells shows MEK inhibitors can mediate decreases in cell proliferation, 
invasion, migration, and anchorage-independent growth in vitro as well as decreased tumor 
growth in vivo in the context of EGFR TKI resistance[262]. Examining other downstream 
signaling molecules that are synergistically inhibited with erlotinib and c-Met TKIs may also 
elucidate other potential co-targets for erlotinib treatment. 
5.2 CONCLUDING REMARKS 
This dissertation has focused on the generation of preclinical models of resistance to 
EGFR targeting agents with the ultimate goal of identifying biomarkers that may predict 
response to these agents and/or serve as molecular co-targets with EGFR inhibitors.  I have 
investigated the generation of cetuximab-resistant HNSCC models using both HNSCC cell line 
derived xenografts and heterotopic tumorgrafts, with the latter being potentially more 
representative of clinical response to cetuximab.   
I have generated a peer-reviewed model of cetuximab resistance in vivo using bladder 
cancer cell line derived xenografts and showed that, in line with my original hypothesis, HER2 
signaling, as identified by 611-CTF and cortactin phosphorylation, may contribute in part to the 
cetuximab resistant phenotype.   
In contrast, I have not identified any positive correlations between HER2, HER3, and c-
Met activity with regard to erlotinib response in HNSCC cells.   However, the requirement for 
both EGFR and c-Met TKIs to decrease activity of MAPK in the presence of EGF and HGF 
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suggests a potential role for pursuing inhibition of MAPK either through these receptors or their 
downstream signaling molecules.   
As a whole, this body of work demonstrates the limitations of using cell lines and cell 
line derived xenografts as models to reflect the heterogeneous responses to EGFR targeting 
agents in the clinic.  However, these studies also suggest that validated preclinical models may 
be useful tools with which to examine biomarkers of EGFR inhibitor response and to identify 
potential novel co-targets. 
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